NOVEL COMPOUNDS

Abstract: The invention provides compounds of general formula (I) wherein: R<1> represents optionally substituted C1-C12 alkyl or optionally substituted 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0-1; Q represents OCH2, C1-C4 alkylene or C2-C4 alkenylene; T represents C(O)NH, or when m is 0, T may additionally represent a bond or NH, or when m is 1 and Q represents C1-C4 alkylene, T may additionally represent NH; n is 1-4; each R<2> and R<3> independently represents H or C1-C4 alkyl; V represents N, and W represents N or CH; X represents O, C(O), CH(OH), SO2, NH or N(C1-C6 alkyl), provided that when W represents N, then X represents either C(O) or SO2 and when W represents CH, then X is other than SO2; R<4> represents optionally substituted phenyl; R<5> and R<6> each independently represent H, C1-C6 alkyl or hydroxyC1-C6 alkyl, or R<5> and R<6> together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; R<7> and R<8> each independently represent H or C1-C6 alkyl; and R<9> represents OH or -NR<7>R<8>; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Description: NOVEL COMPOUNDS The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity. The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2). The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l and lβ (MlP-lα and MlP-lβ). Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above. Certain piperidinyl derivatives and piperazinyl derivatives are known from U.S. Patents Nos. 3 787 419, 4 559 349 and 5 210 086 for use respectively as central nervous system depressants, antipsychotic agents and as αι-adrenoreceptor antagonists. In accordance with the present invention, there is therefore provided a compound of general formula wherein: R represents a C1 -C12 alkyl group optionally substituted by one or more substituents independently selected from cyano, hydroxyl, Ci-Cg alkoxy, C1-C6 alkylthio and alkoxycarbonyl groups, or R represents a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur, the ring system being optionally substituted by one or more substituents independently selected from halogen atoms, and cyano, nitro, hydroxyl, Cj-C6 alkyl, C3-C6 cycloalkyl, Ci-Cβ alkoxy, Cj-Cg alkoxycarbonyl, Cj-Cό haloalkyl, -C6 haloalkoxy, -NR R , C3-C6 cycloalkylamino, alkylthio, Ci-Cβ alkylthioCj-Cg alkyl, 7 8 Ci-Cg alkylcarbonylamino, -C(O)NR R , sulphonamido (-SO2NH2), (di)Cι-C f 5 alkylsulphonamido, phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, 9 benzodioxanyl, thienyl, furanyl, and C(O)R -substituted Ci-C alkyl or Cι-C6 alkoxy groups; m is 0 or 1; Q represents a group OCH2, C1 -C4 alkylene or C2-C4 alkenylene; T represents a group C(O)NH, or when m is 0, T may additionally represent a bond or a group NH, or when m is 1 and Q represents C1-C4 alkylene, T may additionally represent a group NH; n is 1, 2, 3 or 4; 2 each R independently represents a hydrogen atom or a Ci -C4 alkyl group; 3 each R independently represents a hydrogen atom or a C1-C4 alkyl group; V represents a nitrogen atom; W represents a nitrogen atom or a group CH; X represents an oxygen atom or a group C(O), CH(OH), NH or N(Cι-C6 alkyl), provided that when W represents a nitrogen atom, then X represents C(O); 4 R represents a phenyl group optionally substituted by one or more substituents independently selected from halogen atoms, and amino, nitro, cyano, sulphonyl (-SO3H), sulphonamido (-SO2NH2), Ci-Cg alkyl, Ci-Cg haloalkyl, Cj-Cό haloalkoxy and Cj-C alkylsulphonyl groups; R and R each independently represent a hydrogen atom or a -Cg alkyl or hydroxyCι-C6 alkyl group, or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; 7 8 R and R each independently represent a hydrogen atom or a Ci-Cβ alkyl group; and 9 7 8 R represents a hydroxyl or -NR R group; with the provisos that 2 3 (a) when m is 0, T is CONH, n is 2, 3 or 4 and each R and R represents hydrogen, W is CH, X is C(O) or CH(OH) and R represents a substituted 3- to 10-membered unsaturated ring system, then the one or more substituents in the ring system do not include hydroxyl, halogen, Cj-Cg alkoxy or C1-C6 haloalkoxy, and 4 (b) when W is N, X is C(O), R represents 3-trifluoromethylphenyl, m is 0 and T is a 1 2 3 bond, then R and (CR R ) n taken together do not represent a Cj-Cg alkyl group, and 2 3 (c) when W is CH, X is O, n is 2 or 3 and each R and R represents hydrogen, m is 0 and T is NH, then R does not represent a group or a pharmaceutically acceptable salt or solvate thereof. In the context of the present specification, an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched. Further, the alkyl moieties in a dialkylamino, di(hydroxyalkyl)amino or dialkylsulphonamido substituent group may be the same or different. R represents a C1-C12, preferably C1-C10, alkyl group optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from cyano, hydroxyl, C\-C^, preferably -C4, alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy), Cj-Cg, preferably -C4, alkylthio (e.g. methyl-, ethyl-, propyl-, butyl-, pentyl- or hexylthio) and Cj-Cg, preferably -C4, alkoxycarbonyl (e.g. methoxy-, ethoxy-, propoxy-, butoxy-, pentoxy- or hexoxycarbonyl) groups, or R represents a 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur, the ring system being optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen atoms (fluorine, chlorine, bromine or iodine), and cyano, nitro, hydroxyl, -C6 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl or hexyl), C3-C6 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C1-C6 alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy), Cj-Cg alkoxycarbonyl (e.g. methoxy-, ethoxy-, propoxy-, butoxy-, pentoxy- or hexoxycarbonyl), Cj-Cg haloalkyl (e.g. trifluoromethyl), Cj-Cg haloalkoxy (e.g. trifluoromethoxy), -NR R , C3-C6 cycloalkylamino (cyclopropyl-, cyclobutyl-, cyclopentyl- or cyclohexylamino), Cj-Cg alkylthio (e.g. methyl-, ethyl-, propyl-, butyl-, pentyl- or hexylthio), Cj-Cό alkylthioCι-C6 alkyl (e.g. methylthiomethyl), Ci-Cg alkylcarbonylamino (e.g. methyl-, ethyl-, propyl-, butyl-, pentyl- or 7 8 hexylcarbonylamino), -C(O)NR R , sulphonamido (-SO2NH2), (di)Cι-Cg alkylsulphonamido (e.g. (di)methylsulphonamido or (di)ethylsulphonamido), phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, 9 furanyl, and C(O)R -substituted C1-C6 alkyl or Cj-Cό alkoxy groups, the alkyl and alkoxy moieties being as defined above. The 3- to 10-membered saturated or unsaturated ring system in the group R may be monocyclic, or polycyclic comprising 2 or more fused rings, examples of which include cyclobutyl, cyclopentyl, cyclohexyl, norbornylenyl, adamantyl, piperidyl, phenyl, naphthyl, naphthyridinyl, 1,3-benzodioxolyl, pyrazolyl, furanyl, pyridyl, thienyl, benzoxazolyl, benzothiazolyl, chromonyl, imidazolyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyrimidinyl, pyrazolopyrimidinyl, thienopyrimidinyl, thiazolopyrimidinyl, pyrimidinedione, pyrazinyl, pyridazinyl, purinyl, quinoxalinyl, thiazolyl, isothiazolyl and 2,4-dioxo-3,4-dihydro-quinazolinyl. Preferably, R represents a C1-C10 alkyl group optionally substituted by one or two substituents independently selected from cyano, hydroxyl, C1-C4 alkoxy, C1-C4 alkylthio and C1-C4 alkoxycarbonyl groups, or R represents a 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur, the ring system being optionally substituted by one, two or three substituents independently selected from halogen atoms, and cyano, nitro, hydroxyl, -C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C1-C4 alkoxycarbonyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, -NR R , C3-C6 cycloalkylamino, C1 -C4 alkylthio, C1-C4 alkyl thioCj-C4 alkyl, 7 8 C1-C4 alkylcarbonylamino, -C(O)NR R , phenyl, phenylamino, nitrophenyl, pyridyl, 9 pyridylthio, benzodioxanyl, thienyl, furanyl, and C(O)R -substituted C1 -C4 alkyl or C1 -C4 alkoxy groups. Preferably Q represents a group OCH2, C1-C3 alkylene or C2-C3 alkenylene. 2 Each R independently represents a hydrogen atom or a C1-C4 alkyl (e.g. methyl, ethyl, propyl, isopropyl or butyl) group, and is especially a hydrogen atom. 3 Each R independently represents a hydrogen atom or a -C4 alkyl (e.g. methyl, ethyl, propyl, isopropyl or butyl) group, and is especially a hydrogen atom. Preferably n is 2 or 3. X preferably represents an oxygen atom or a group C(O) or NH. 4 R represents a phenyl group optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen atoms (fluorine, cholorine, bromine or iodine), and amino, nitro, cyano, sulphonyl (-SO3H), sulphonamido (-SO2NH2), C1-C6, preferably C1 -C4, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl), Ci- , preferably -C4, haloalkyl (e.g. trifluoromethyl), Cj-Cβ, preferably C1-C4, haloalkoxy (e.g. trifluoromethoxy) and Ci-Cg, preferably C1-C4, alkylsulphonyl (e.g. methyl-, ethyl-, propyl-, butyl-, pentyl- or hexylsulphonyl) groups. 4 Preferably, R represents a phenyl group optionally substituted by one or two halogen atoms, particularly chlorine atoms. R and R each independently represent a hydrogen atom or a Cj-Cg, preferably -C4, alkyl or hydroxy -Cό, preferably C1-C4, alkyl group, or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring. The alkyl moiety in each case may, for example, be a methyl, ethyl, propyl, butyl, pentyl or hexyl group. In the hydroxyalkyl group, the hydroxyl group may be attached to any suitable carbon atom of the alkyl moiety. 7 8 R and R each independently represent a hydrogen atom or a Ci -Cg, preferably C1-C4, 7 8 alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) group. Preferably, R and R each independently represent a hydrogen atom or a methyl group. 9 5 6 R represents a hydroxyl or, preferably, -NR R group. Examples of particularly preferred compounds of the invention include: 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2-[2-(dimethylamino)-2- oxoethoxy]benzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- -piperidinyljethyl } -3-ethoxybenzamide hydrochloride, N- { 2-[4-(3 ,4-Dichlorophenoxy)- -piperidinyl]ethyl } -4-isopropoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- -piperidinyl]ethyl } -4-ethoxybenzamide, N- { 2- [4-(3 J-Dichlorophenoxy)- -piperidinyl]ethyl } -3-(trifluoromethoxy)benzamide hydrochloride, N-{2-[4-(3,4-Dichlorophenoxy)- -piperidinyl]ethyl}-4-methoxybenzamide, N- { 2- [4-(3 J-Dichlorophenoxy)- -piperidmyljethyl } -4-(trifluoromethoxy)benzamide hydrochloride, N- { 2-[4-(3,4-Dichlorophenoxy)- -piperidinyljethyl }-2-furamide hydrochloride, N- { 2- [4-(3 ,4-Dichlorophenoxy)- -piperidmyljethyl } -2-phenylacetamide hydrochloride, N- { 2-[4-(3.4-Dichlorophenoxy)- -piperidinyljethyl } -3-methoxybenzamide hydrochloride, 3-Chloro-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide hydrochloride, N- { 2- [4-(3 ,4-Dichlorophenoxy)- -piperidinyljethyl } -4-fluorobenzamide, N-{2-[4-(3,4-Dichlorophenoxy)- -piperidinyljethyl } -3-fluorobenzamide hydrochloride, N-{ 2-[4-(3,4-Dichlorophenoxy)- -piperidinyljethyl } -3-hydroxybenzamide hydrochloride, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl }-3-[2-(methylamino)-2- oxoethoxyjbenzamide hydrochloride, 2-[3-{2-[4-(4-Fluorobenzoyl)-l-piperidinylJethyl}-2J-dioxo-3J-dihydro-l(2H)- quinazolinyl]-N,N-dimethylacetamide hydrochloride, N- { 2-[4-(3,4-Dichlorobenzoyl)- 1 -piperazinyljethyl } -3-methoxybenzamide hydrochloride, 3,4-Dichloro-N-{2-[4-(3,4-dichlorobenzoyl)J -piperazinyljethyl Jbenzamide, 4-Chloro-N- { 2-[4-(3,4-dichlorobenzoyl)- 1 -piperazinyljethyl }-2-[2-(dimethylamino)-2- oxoethoxyjbenzamide hydrochloride, N~7~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-5-methyl[l,3]thiazolo[4,5- d]pyrimidine-2,7-diamine, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinylJethyl}-9-methyl-9H-purin-6-amine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-benzothiazol-2-amine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-benzoxazol-2-amine, 6-Chloro-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -2-pyrazinamine, 6-Chloro-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl }-3-pyridazinamine, 6-( { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } amino)- 1 ,3-dimethyl-2,4( 1 H,3H)- pyrimidinedione, N- { 1 -[4-(3,4-Dichlorophenoxy)-piperidin- 1 -ylmethyl] -2-methyl-propyl } -4-methyl- benzamide, hydrochloride salt, N-{ l-[4-(3,4-Dichloro-phenoxy)-piperidin-l-ylmethylJ-2-methyl-propyl}-3-methoxy- benzamide, hydrochloride salt, N-{2-[4-(3,4-Dichloroanilino)-l-piperidinyl]ethyl}-3-methoxybenzamide dihydrochloride, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-N-(3-methoxybenzyl)amine dihydrochloride, 3-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-6-methoxy-2,4(lH,3H)- quinazolinedione, N-{2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-3-fluorobenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl Jbenzamide, 4-Chloro-N-{2-[4-(3J-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-methoxybenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-methoxybenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-3-methoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-nitrobenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-methylbenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-(trifluoromethyl)benzamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-3,5-dinitrobenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-iodobenzamide, 4-Cyano-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyl] ethyl } benzamide, 4-Bromo-N-{2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl Jbenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-methylbenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-nitrobenzamide, 3-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide, 3 ,4-Dichloro-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-fluorobenzamide, 2,4-Dichloro-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-methylbenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-iodobenzamide, 4-Chloro-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -3-nitrobenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-methyl-3-nitrobenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-fluoro-5- (trifluoromethyl)benzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-(trifluoromethoxy)benzamide, 3,5-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(trifluoromethyl)benzamide, 3-Cyano-N-{2-[4-(3J-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide, 2-Bromo-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -5-methoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-furamide, 3-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide, 2-Chloro-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-3,5-difluorobenzamide, 2,3-Dichloro-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide, N-{ 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2-naphthamide, N-{ 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2-(methylsulfanyl)nicotinamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-fluoro-6- (trifluoromethyl)benzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,4-difluorobenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-2-thiophenecarboxamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-quinoxalinecarboxamide, Methyl 4-({ 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } amino)-4-oxobutanoate, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}bicyclo[2.2J]hept-5-ene-2- carboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl jcyclobutanecarboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-methoxyacetamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}cyclohexanecarboxamide, (E)-N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-phenyl-2-propenamide, 2-Chloro-N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}nicotinamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-phenylacetamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}cyclopentanecarboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-phenoxyacetamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } benzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-(trifluoromethyl)benzamide, 4-(tert-Butyl)-N-{2-[4-(4-chlorobenzoyl)-l -piperidinyljethyl jbenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -4-methylbenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -4-nitrobenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-methylbenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -4-methyl-3-nitrobenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-cyanobenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-furamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-nitrobenzamide, N- { 2- [4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-naphthamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-(methylsulfanyl)nicotinamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-(2,3-dihydro- 1 ,4-benzodioxin-2-yl)- 1,3- thiazole-4-carboxamide, N~2~-Cyclopropyl-N~4~-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2J- pyrimidinediamine, 2- { [4-( { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } amino)-2-pyrimidinyl] amino } - 1 - ethanol, 2-[[4-( { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } amino)-2- pyrimidinyl](methyl)amino]- 1 -ethanol, N~4~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-N~2~-phenyl-2J- pyrimidinediamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(methylsulfanyl)-4-pyrimidinamine, N~4— { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -6-methyl-2 ,4-pyrimidinediamine, N~4~- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -N~2~,6-dimethyl-2,4- pyrimidinediamine, 2-Chloro-N~4~-cyclopropyl-N~6~- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -4,6- pyrimidinediamine, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-phenyl-2-pyrimidinamine, N~2~-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-N~4~,N~4~,6-trimethyl-2J- pyrimidinediamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(trifluoromethyl)-2- pyrimidinamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(propylsulfanyl)-2-pyrimidinamine, N~2~-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-N~4~-phenyl-2J- pyrimidinediamine, N~4~-Cyclopropyl-N~2~-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2J- pyrimidinediamine, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }[l,8Jnaphthyridin-2-amine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-4-(3-pyridinyl)-2-pyrimidinamine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-pyrimidinamine, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-4,6-dimethoxy-2-pyrimidinamine, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-4-(3-furyl)-2-pyrimidinamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 -methyl- 1 H-pyrazolo [3 ,4- d]pyrimidin-4-amine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 H-purin-6-amine, N- {2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-5-methylthieno[2,3-d]pyrimidin-4- amine, N-{ 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-7-methylthieno[3,2-dJpyrimidin-4- amine, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-thiophenecarboxamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-quinoxalinecarboxamide, N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyl}bicyclo[2.2J]hept-5-ene-2-carboxamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } cyclohexanecarboxamide, (E)-N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-phenyl-2-propenamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-phenoxyacetamide, (E)-N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-(4-nitrophenyl)-2-propenamide, 2-( 1 -Adamantyl)-N- { 2-[4-(4-chlorobenzoyl)- 1 -piperidinyljethyl } acetamide, (4-Chlorophenyl)( 1 - { 2-[(2-fluoro-4,5-dimethoxybenzyl)amino]ethyl } -4- piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(3J,5-trimethoxybenzyl)aminoJethyl}-4-piperidinyl)methanone, (4-Chlorophenyl)( 1 - { 2-[(3-nitrobenzyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl){ l-[2-(isobutylamino)ethylJ-4-piperidinyl}methanone, 4-[( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methylJ-4-ethylhexanenitrile, (4-Chlorophenyl)(l-{2-[(7-hydroxy-3,7-dimethyloctyl)amino]ethyl}-4- piperidinyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [(6-nitro- 1 ,3-benzodioxol-5-yl)methyl]amino } ethyl)-4- piperidinyljmethanone, [ 1 -(2- { [(5-Chloro- 1 ,3-dimethyl- 1 H-pyrazol-4-yl)methylJ amino } ethyl)-4-piperidinyl] (4- chlorophenyl)methanone, (4-Chlorophenyl)[l-(2-{ [3-nitro-4-(2-pyridinylsulfanyl)benzyl]amino}ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(E)-3-(4-nitrophenyl)-2-ρropenyl] amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) { l-[2-({ [5-(3-nitrophenyl)-2-furyl]methyl }amino)ethyl]-4- piperidinyl jmethanone, (4-Chlorophenyl) [ 1 -(2- { [5-nitro-2-(2-pyridinylsulf anyl)benzyl] amino } ethyl)-4- piperidinyljmethanone, 6- [( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyl] ethyl } amino)methyl] -2- (methylsulfanyl)nicotinonitrile, { 1 -[2-( { [5-Chloro- 1 -methyl-3-(trifluoromethyl)- 1 H-pyrazol-4-yl]methyl } amino)ethyl]-4- piperidinyl } (4-chlorophenyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [3-(methylsulfanyl)butyl] amino } ethyl)-4-piperidinyl] methanone, (4-Chlorophenyl) [ 1 -(2- { [(4-phenyl-4-piperidinyl)methyl]amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [( 1 -phenyl- 1 H-pyrazol-5-yl)methyl]amino } ethyl)-4- piperidinyljmethanone, Ethyl 3-[( { 2-[4-(4-chlorobenzoyl)- 1 -piperidinyljethyl } - amino)methyl]cyclohexanecarboxylate, N- {4-[( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methylJphenyl } acetamide, (4-Chlorophenyl)( 1 - { 2-[(2,5-difluorobenzyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl)( 1 - { 2-[(4-nitrobenzyl)aminoJethyl } -4-piperidinyl)methanone, (4-Chlorophenyl) ( 1 - { 2-[(2,6-dichlorobenzyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl)( 1 - { 2-[(2-pyridinylmethyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [(3-methyl-2-thienyl)methylJ amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl)( 1 - { 2-[(3-hydroxy-4-methoxybenzyl)aminoJethyl } -4- piperidinyl)methanone, 3-[({2-[4-(4-Chlorobenzoyl)-l -piperidinyljethyl }amino)methylJ-4H-chromen-4-one, [1 -(2- { [(5-Chloro- 1,3-dimethyl-l H-pyrazol-4-yl)methyl] amino }ethyl)-4-piperidinyl] (4- chlorophenyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [(2,6-dichloro-4-pyridinyl)methylJ amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl)[ 1 -(2- { [(2-phenyl- 1 H-imidazol-4-yl)methyl] amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl)[l-(2-{[(5-ethyl-2-thienyl)methylJamino}ethyl)-4-piperidinyl]methanone, (4-Chlorophenyl)[l-(2-{ [(2-chloro-3-quinolinyl)methyl]amino}ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(6-methyl-2-pyridinyl)methylJ amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl)( 1 - { 2-[(3-quinolinylmethyl)amino]ethyl } -4-piperidinyl)methanone, 4-[( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methylJ- 1 ,5-dimethyl-2-phenyl- 1 ,2-dihydro-3H-pyrazol-3-one, (4-Chlorophenyl)( 1 - { 2-[(4-pyridinylmethyl)aminoJefhyl } -4-piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(3-hydroxy-4-nitrobenzyl)amino]ethyl}-4-piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(3,5-difluorobenzyl)aminoJethyl}-4-piperidinyl)methanone, ( 1 - { 2-[(2-Chloro-6-fluorobenzyl)amino]ethyl } -4-piperidinyl)(4-chlorophenyl)methanone, [l-(2-{[(4-Bromo-lH-pyrazol-3-yl)methylJamino}ethyl)-4-piperidinyl](4- chlorophenyl)methanone, 3-[({2-[4-(4-Chlorobenzoyl)-l -piperidinyljethyl }amino)methyl]-6,7-dimethyl-4H- chromen-4-one, 2- { 2-[( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methylJ-4-nitrophenoxy } acetic acid, (4-Chlorophenyl) [ 1 -(2- { [( 1 -methyl- 1 H-benzimidazol-2-yl)methylJamino } ethyl )-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(2,4-dimethoxy-5-pyrimidinyl)methyl]amino } ethyl)-4- piperidinyljmethanone, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(methylamino)benzamide, 4-Chloro-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-3-methoxy-4-methylbenzamide, 3-Amino-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-4-methoxybenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-benzodioxole-5-carboxamide, 4-Amino-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-fluoro-4-methoxybenzamide, 5-Bromo-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -2-furamide, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-3-methyl-2-furamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-4,5-dimethyl-2-furamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -7-ethoxy- 1 -benzofuran-2- carboxamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-5-methoxy- 1 -benzofuran-2- carboxamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-7-methoxy-l-benzofuran-2- carboxamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(4-fluorophenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(2-methoxyphenyl)acetamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3-methylphenyl)acetamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(2-methylphenyl)acetamide, 2-(3-Bromophenyl)-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } acetamide, 2-(2-Chlorophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}acetamide, 2-(4-Chlorophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l -piperidinyljethyl} acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinylj ethyl } -2- [2- (trifluoromethyl)phenyljacetamide, 2-(3-Chlorophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l -piperidinyljethyl} acetamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(3,4-dimethoxyphenyl)acetamide, N-{ 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2-(4-methoxyphenyl)acetamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(3,4-dichlorophenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinylj ethyl } -2-(3-fluoro-4- methoxyphenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2-(4-ethoxyphenyl)acetamide, 2-( 1 ,3-Benzodioxol-5-yl)-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } acetamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-[4- (dimethylamino)phenyljacetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(4-methylphenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinylj ethyl } -2-(3 ,4-difluorophenyl)acetamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3-methoxyphenyl)acetamide, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-4-phenylbutanamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinylJethyl}-3-phenylpropanamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-(3-methoxyphenyl)propanamide, 2-Amino-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl }- 1 ,3-thiazole-4-carboxamide, 2-(Acetylamino)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-l ,3-thiazole-4- carboxamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(4-pyridinyl)-l,3-thiazole-4- carboxamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,4-dimethyl- 1 ,3-thiazole-5- carboxamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,5-dimethyl- 1 ,3-oxazole-4- carboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 H-imidazole-4-carboxamide, N-{2-[4-(3,4-Chlorophenoxy)-l -piperidinyljethyl} -3-methoxybenzamide, hydrochloride salt, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1-methyl- 1 H-pyrazolo[3,4- d]pyrimidin-4-amine, N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-2,6-dimethoxy-4-pyrimidinamine, N~4~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-N~2~,N~2~-dimethyl-2J- pyrimidinediamine, N-{3-[4-(3J-Dichlorophenoxy)-l-piperidinyl]propyl}-2-[(methylsulfanyl)methyl]-4- pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-2-(methylsulfanyl)-6- (trifluoromethyl)-4-pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-methoxy-2-(methylsulfanyl)-4- pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-6-methyl-2-(methylsulfanyl)-4- pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-mefhoxy-2-methyl-4- pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2-(ethylsulfanyl)-6-methyl-4- pyrimidinamine, N~2~-Cyclopropyl-N~4~- { 3-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljpropyl } -2,4- pyrimidinediamine, 2- { [4-( { 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-2-pyrimidinyl] amino } - 1 - ethanol, 2-[[4-({3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}amino)-2- pyrimidinyl](methyl)amino]-l-ethanol, N- { 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2-(methylsulf anyl)-4- pyrimidinamine, N~4~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-6-methyl-2,4- pyrimidinediamine, N~4~-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-N~2~, 6-dimethyl-2,4- pyrimidinediamine, N-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-4-phenyl-2-pyrimidinamine, N~2~- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-fluoro-2,4-pyrimidinediamine, N~2~- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -N~4~,N~4~,6-trimethyl-2,4- pyrimidinediamine, N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-4-(trifluoromethyl)-2- pyrimidinamine, N- { 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -4-(propylsulf anyl)-2- pyrimidinamine, N-2— { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -N~4— phenyl-2,4- pyrimidinediamine, N~2— { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -N~4~,6-dimethyl-2,4- pyrimidinediamine, N-{ 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }[l,8]naphthyridin-2-amine, 2- { [2-( { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-4-pyrimidinyl]amino } - 1 - ethanol, 2- [ [2-( { 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-4- pyrimidinyl] (methyl)aminoj - 1 -ethanol , N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -4-(3-pyridinyl)-2-pyrimidinamine, N-{ 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-4-(3-thienyl)-2-pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyrimidinamine, N-{3-[4-(3,4-Dichlorophenoxy)J -piperidinyljpropyl }-4,6-dimethoxy-2-pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-4-(3-furyl)-2-pyrimidinamine, N-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-4-(2-thienyl)-2-pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 H-purin-6-amine, N-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-5-methylthieno[2,3-d]pyrimidin-4- amine, N-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-7-methylthieno[3,2-d]pyrimidin-4- amine, N~7~- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-methyl [ 1 ,3]thiazolo[4,5- d]pyrimidine-2,7-diamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -9-methyl-9H-purin-6-amine, N-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-2-pyridinamine, 5-Chloro-N-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-2-pyridinamine, 6-Chloro-N-{3-[4-(3,4-dichlorophenoxy)J -piperidinyljpropyl }-2-pyridinamine, N-{3-[4-(3J-Dichlorophenoxy)-l-piperidinylJpropyl}-6-methyl-2-pyridinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 ,3-benzothiazol-2-amine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 ,3-benzoxazol-2-amine, 6-Chloro-N- { 3-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyrazinamine, 6-Chloro-N-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-3-pyridazinamine, 6-( { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)- 1 ,3-dimethyl-2,4( 1 H,3H)- pyrimidinedione, N-{ 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2,6-dimethoxy-4-pyrimidinamine, N~4~-{2-[4-(3,4-Dichlorophenoxy)-l-piρeridinyl]ethyl}-N~2~,N~2~-dimethyl-2J- pyrimidinediamine, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-[(methylsulfanyl)methyl]-4- pyrimidinamine, N- {2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-5-methoxy-2-(methylsulfanyl)-4- pyrimidinamine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -6-methyl-2-(methylsulfanyl)-4- pyrimidinamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -5-methoxy-2-methyl-4- pyrimidinamine, and N~4~- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -6-methyl-N~2~-phenyl-2,4- pyrimidinediamine. The present invention further provides a process for the preparation of a compound of formula (I) which comprises (i) when T represents a group C(O)NH, reacting a compound of general formula «^-∞^ <H) wherein L represents a leaving group (e.g. a hydroxyl or halide, such as chloride, group) and R , m and Q are as defined in formula (I), with a compound of general formula 2 3 4 or an acid addition salt thereof (e.g. trifluoroacetate) wherein n, R , R , V, W, X and R are as defined in formula (I); or (ii) when T represents a group C(O)NH and W represents a nitrogen atom, reacting a compound of general formula R 1 — (Q) m — T— 1 2 3 wherein R , m, Q, T, n, R , R and V are as defined in formula (I), with a compound of general formula 2 4 L - X - R (V) 2 4 wherein L represents a leaving group (e.g. a halogen atom) and X and R are as defined in formula (I); or (iii) when T represents a group NH and m is 0, reacting a compound of general formula R 1 - L 3 (VI) 3 1 wherein L represents a leaving group (e.g. a halogen atom) and R is as defined in formula (I), with a compound of formula (HI) as defined in (i) above; or (iv) when T represents a group NH, m is 1 and Q represents -C4 alkylene, reacting a compound of general formula F -(CH 2 ) P -CHO __ wherein p is 0, 1 , 2 or 3 and R is as defined in formula (I), with a compound of formula (HI) as defined in (i) above; or (v) when T represents a bond and m is 0, reacting a compound of general formula R 1 -(CR 2 R 3 ) n -L 4 (Vm) 4 1 2 wherein L represents a leaving group such as a halogen atom (e.g. chlorine) and n, R , R 3 and R are as defined in formula (I), with a compound of general formula (IX) 4 wherein W, X and R are as defined in formula (I); and optionally after (i), (ii), (iii), (iv) or (v) converting the compound of formula (I) to a further compound of formula (I) and/or forming a pharmaceutically acceptable salt or solvate of the compound of formula (I). The processes of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as dimethylformamide or dichloromethane at a temperature of, for example, 15°C or above such as a temperature in the range from 20 to 100°C. Compounds of formula (HI) in which W represents a nitrogen atom may be prepared by reacting a compound of general formula 2 3 in which n, R , R and V are as defined in formula (I) with a compound of formula (V) as defined above. Compounds of formula (X) can be prepared by reacting piperazine with a compound of general formula 5 2 3 wherein L represents a halogen atom such as a bromine atom and n, R and R are as defined in formula (I). Compounds of formula (HI) in which W represents a group CH and X represents an oxygen atom may be prepared by reacting a compound of general formula 4 in which R is as defined in formula (I), with a compound of formula (XI). Compounds of formula (XII) may be prepared by reacting 4-piperidinol with a compound 4 4 of general formula (XHT), R -OH, wherein R is as defined in formula (I), in the presence of a coupling agent such as diethyl azodicarboxylate and triphenylphosphine and in a solvent such as benzene or tetrahydrofuran at a temperature typically in the range from 20 to 30 °C. Compounds of formula (HI) in which W represents a group CH and X represents a group C(O) may be prepared by reacting a compound of general formula 4 wherein R is as defined in formula (I), with a compound of formula (XI). Compounds of formula (HI) in which W represents a group CH and X represents a group CH(OH) may be prepared by reducing/hydrogenating a corresponding compound of formula (HI) in which X represents C(O) using techniques known in the art. Compounds of formula (HI) in which W represents a group CH and X represents a group NH may be prepared by reacting a compound of general formula 4 in which R is as defined in formula (I), with a compound of formula (XI). Compounds of formula (XV) may be prepared by reacting 4-piperidone with a compound 4 4 of general formula (XVI), R -NH2, wherein R is as defined in formula (I), in the presence of a reducing agent such as sodium cyanoborohydride or sodium borohydride and in a solvent such as methanol or benzene at a temperature typically in the range from 20 to 90 °C. Compounds of formula (HI) in which W represents a group CH and X represents a group N(Cι-C6 alkyl) may be prepared by alkylating a corresponding compound of formula (HI) in which X represents a group NH, using techniques conventional in the art. Compounds of formula (IV) may be prepared by reacting a compound of formula (H) with a compound of formula (X). Compounds of formulae H, V, VI, VH, VHI, JX, XI, XHI, XIV and XVI are either commercially available, are well known in the literature or may be prepared easily using known techniques. Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures. For example, compounds of formula (I) in which R represents an alkoxy-substituted phenyl group can be converted to compounds of formula (I) in which R represents a hydroxy-substituted phenyl group by reaction with boron tribromide in a solvent such as dichloromethane. Further, compounds of formula (I) in which X represents C(O) can be converted to compounds of formula (I) in which X represents CH(OH) by reaction with triethylsilane and trifluoroacetic acid in a solvent such as dichloromethane. It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is described in Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley- Interscience (1991). The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or /?-toluenesulphonate. Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCRl and/or CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS). Examples of these conditions are: (1) (the respiratory tract) obstructive airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia; (2) (bone and joints) rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis; (3) (skin) psoriasis, atopical dermatitis, contact dermatitis and other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis; (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema; (5) (other tissues and systemic disease) multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura; and (6) (allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease. Thus, the present invention provides a compound of formula (I), or a pharmaceutically- acceptable salt or solvate thereof, as hereinbefore defined for use in therapy. In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy. In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly. The invention also provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined. For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0J0 to 70 %w, and even more preferably from 0J0 to 50 %w, of active ingredient, all percentages by weight being based on total composition. The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier. The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier. The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. The invention will now be further explained by reference to the following illustrative examples. Example 1 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyI}-2-[2-(dimethylamino)-2- oxoethoxy J benzamide (i) tert-Butyl 4-(3,4-dichlorophenoxy)-l-piperidinecarboxylate Diethyl azodicarboxylate (12.6ml) was added to a solution of triphenylphosphine (20.8g) in tetrahydrofuran (300ml) at 0° C. After 15 minutes 3,4-dichlorophenol (12.9g) was added, after a further 10 minutes tert-butyl 4-hydroxy-l-piperidinecarboxylate (14.5g) in tetrahydrofuran (100ml) was added dropwise over 0.5 hour. The solution was stirred at room temperature for 5 hours and concentrated to a small volume. The residue was partitioned between ether and brine. The organic phase was separated, dried and evaporated to a gum. Purification by chromatography (ethyl acetate : isohexane 95:5) gave the sub-titled product as an oil (20g). MS: APCI(+ve): 246 (M-BOC+2H) (ii) 4-(3,4-Dichlorophenoxy)piperidine The product from step (i) was dissolved in dichloromethane (200ml) and trifluoroacetic acid (100ml) was added. After 18 hours at room temperature the solution was evaporated and the resultant gum triturated under ether to give the sub-titled product as a solid (16.2g). (iii) tert-Butyl 2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethylcarbamate The product from step (ii) (6.55g) was dissolved in DMF (50ml) and triethylamine (7.9ml) was added. tert-Butyl 2-bromoethylcarbamate (4.3 g) in DMF (5ml) was added and the solution stirred at room temperature for 3 days. Ethyl acetate and water were added, the organic phase separated, dried and evaporated to a gum. Purification by chromatography (dichloromethane : methanol 95:5) gave the sub-titled product as a gum (5.7g). MS: APCI(+ve): 389(M+H) (iv) 2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethylamine trifluoroacetate The product from step (iii) was dissolved in dichloromethane (200ml) and trifluoroacetic acid (100ml) added. After 18hrs at room temperature the solvent was evaporated and the resultant gum triturated under ether to give the sub-titled product as a solid (5.7g). MS: APCI(+ve): 290(M+H) (v) 2-(Dimethylamino)-2-oxoethyl 4-chloro-2-[2-(dimethylamino)-2- oxoethoxyjbenzoate A mixture of 4-chloro-2-hydroxybenzoic acid (5g), Cs CO 3 (17.5g) and 2-chloro-N,N- dimefhylacetamide (6.6g) was stirred and heated at 70 °C for 3 hours. Water and ethyl acetate were added, the organic phase separated, dried and concentrated to a gum which was purified by chromatography (ethyl acetate : methanol, 9: 1) to give the sub-titled product as a solid (8.0g). MS: APCI(+ve) 343(M+H) Melting point: 140-141 °C (vi) 4-Chloro-2-[2-(dimethylamino)-2-oxoethoxyJbenzoic acid The product from step (v) (l.Og) was dissolved in a 2 : 1 water : methanol mixture (15ml) and LiOH.H O added. After 2 hours 2M aqueous HC1 solution and ethyl acetate were added, the organic phase separated, dried and concentrated to give the sub-titled product as a solid (1.2g). MS: APCI(+ve) 258(M+H) Melting point: 141 - 142 °C (vii) 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-2-[2- (dimethylamino) -2-oxoethoxy] benzamide The product from step (vi) (0.3g) and N,N-carbonyldiimidazole (0J9g) were dissolved in DMF (20ml) and the solution stirred at room temperature for 1 hour. The product from step (iv) (0.42g) and triethylamine (0.32ml) were added. After 20 hours water and ether were added, the organic phase separated, dried and concentrated to a gum which was purified by chromatography (dichloromethane : methanol, 93:7) to give the titled product as a solid (0.38g). MS: ESI 528.12 (M+H) H NMR: δ(DMSO) 9J7 (t, 1H), 7.88 (d, 1H), 7.48 (d, 1H), 7.38 (d, 1H), 7.24 (d, 1H), 7J3 (dd, 1H), 6.99 (dd, 1H), 5.1 1 (s, 2H), 4.32 (m, 1H), 3.42 (m, 2H), 2.99 (s, 3H), 2.88 (s, 3H), 2.73 (m, 2H), 2.50 (m, 2H), 2.30 (m, 2H), 1.90 (m, 2H), 1.59 (m, 2H). Melting point: 139-40 °C Example 2 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}-3-ethoxybenzamide hydrochloride The product of Example 1 step (iv) (0.4g) was dissolved in DMF (10ml) , PyBrop (0.54 lg), 3-ethoxybenzoic acid ( 0J67g ) and N,N-di-isopropylethylamine (0.5g) were added. After 18 hours at room temperature chloroform and aqueous NaHCO 3 solution were added. The organic phase was separated, dried and concentrated to leave a gum which was purified by chromatography ( ethyl acetate : methanol 97:3) to give an oil. Addition of l .OM ethereal hydrogen chloride solution gave the titled product as a solid (0J4g). MS: ESI 437.14 (M+H) H NMR: δ(DMSO) 8.87 (bs, 1H), 7.50 (m, 3H), 7.40 (m, 2H), 7.06 (m, 2H), 4.83 / 4.62 (m, 1H ), 4.08 (q, 2H), 3.67 (m, 3H), 3.47 (m, 1H), 3J7 (m, 3H), 2.20 (m, 2H), 2.03 (m, 2H), 1.34 (t, 3H) Melting point: 191-193 °C Example 3 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-isopropoxybenzamide Prepared by the same method as Example 2 using 4-isopropoxybenzoic acid without the addition of 1.0 M ethereal hydrogen chloride solution to give the titled product as a solid (0J2g). MS: ESI 451.14 (M+H) H NMR: δ(DMSO) 8.22 (t, 1H), 7.8 (m, 2H), 7.49 (d, 1H), 7.25 (d, 1H), 7.00 (m, 3H), 4.7 (m, 1H), 4.45 (m, 1H), 3.36 (m, 2H), 2.73 (m, 2H), 2.48 (m, 2H), 2.29 ( m, 2H), 1.91 (m, 2H), 1.60 (m, 2H), 1.28 (s, 3H), 1.27 (s, 3H) Melting point: 113-15 °C Example 4 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-ethoxybenzamide Prepared by the same method as Example 2 using 4-ethoxybenzoic acid without the addition of 1.0 M ethereal hydrogen chloride solution to give the titled product as a solid (OJg). MS: ESI 437.14 (M+H) ! H NMR: δ(DMSO) 8.22 (t, 1H), 7.79 (d, 2H), 7.49 (d, 1H), 7.25 (d, 1H), 7.00 (m, 3H), 4.5 (m, 1H), 4.07 (q, 2H), 3.37 (q, 2H), 2.73 (m, 2H), 2.47 (m, 2H), 2.30 (m, 2H), 1.91 (m, 2H), 1.60 (m, 2H), 1.34 (t, 3H) Melting point: 118-20 °C Example 5 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-(trifluoromethoxy)benzamide hydrochloride Prepared by the same method as Example 2 using 3-trifluoromethoxybenzoic acid to give the titled product as a solid (0J2g). MS: ESI 477.09 (M+H) H NMR: δ(DMSO) 10.42 (bs, 1H), 9.11 (bm, 1H), 8.0 (d, 1H), 7.88 (s, 1H), 7.6 (m, 3H), 7.37 (m, 1H), 7.06 (m, 1H), 4.70 (m, 1H), 3.71 (m, 3H), 3.48 (d, 1H), 3.20 (m, 4H), 2.2 (m, 4H) Melting point: 180-82 °C Example 6 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-methoxybenzamide Prepared by the same method as Example 2 using 4-methoxybenzoic without the addition of 1.0 M ethereal hydrogen chloride solution to give the titled product as a solid (0J lg). MS: ESI 423.12 (M+H) ! H NMR: δ(DMSO) 8.42 (t, 1H), 7.81 (m, 2H), 7.49 (d, 1H), 7.25 (d, 1H), 6.98 (s, 3H), 4.4 (mJH), 3.8 (s, 3H), 3.35 (q, 2H), 2.73 (m, 2H), 2.47 (m, 2H), 2.30 (m, 2H), 1.91 (m, 2H), 1.60 (m, 2H) Melting point: 1 10-12 °C Example 7 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-(trifluoromethoxy)benzamide hydrochloride Prepared by the same method as Example 2 using 4-trifluoromethoxybenzoic acid to give the titled product as a solid (0J9g). MS: ESI 477 (M+H) ! H ΝMR: δ(DMSO) 10.5 (bs, 1H), 9.06 (m, 1H), 8.07 (dd, 2H), 7.55 (t, 1H), 7.49 (d, 2H), 7.36 (dd, 1H), 7.10-7.02 (m, 1H), 4.72 (m, 1H), 3.70 (m, 3H), 3.47 (d, 1H), 3J4 (m, 2H), 2.25 (m, 2H), 2.02 (m, 2H) Melting point: 184-187 °C Example 8 Ν-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-furamide hydrochloride Prepared by the same method as Example 2 using furan-2-carboxylic acid to give the titled product as a solid (0J4g). MS: ESI 383.09 (M+H) *H NMR: δ(DMSO) 10.43 (bm, IH), 8.76 (t, IH), 7.87 (s, IH), 7.55 (t, IH), 7.36 (dd, IH), 7.21 (d, IH), 7.06 (m, IH), 6.64 (dd, IH), 4.83-4.61 (m, IH), 3.65 (m, 3H), 3.45 (d, IH), 3.08 (m, 4H), 2J (m, 4H) Melting point: 225-28 °C Example 9 N-{2-[4-(3,4-DichIorophenoxy)-l-piperidinylJethyl}-2-phenylacetamide hydrochloride Prepared by the same method as Example 2 using phenylacetic acid to give the titled product as a solid (0J2g). MS: ESI 407 (M+H) H NMR: δ(DMSO) 10.28 (bm, IH), 8.46 (bm, IH), 7.56 (t, IH), 7.3 (m, 6H), 7J0 (m, IH), 4.81/4.58 (m, IH), 3.58 (d, IH), 3.46 (m, 4H), 3.10 (m, 4H), 2.15 (m, 5H) Melting point: 135-38 °C Example 10 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-methoxybenzamide hydrochloride The product of Example 1 step (iv) (2.0g) was dissolved in dichloromethane (490ml), triethylamine (1.85ml) and 3-methoxybenzoyl chloride (0.66g) were added. After 72 hours at room temperature, water was added, the organic phase separated, dried and concentrated to a gum. The product was dissolved in dichloromethane and treated with 1.OM ethereal hydrogen chloride solution to give the titled product as a solid (0.88g). MS: ESI 423.12 (M+H) *H NMR: δ(DMSO) 10.6-10.5 (m, IH), 9.92 (s, IH), 7.54 (m, 3H), 7.38 (m, 2H), 7.08 (m, 2H), 4.84/4.62 (m IH), 3.82 (s, 3H), 345 (m, 8H), 2.27 (m, 4H). Melting point: 72-73 °C Example 11 3-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}benzamide hydrochloride The product of Example 1 step (iv) (0J5g) was dissolved in DMF (3ml), N,N-di- isopropylethylamine (0.3ml) and 3-chlorobenzoyl chloride (0.054ml) were added. After 2 hours at room temperature, water and ethyl acetate were added, the organic phase separated dried and concentrated. The residue was purified by chromatography (dichloromethane : methanol, 95:5) to give an oil which was dissolved in ether and l.OM ethereal hydrogen chloride solution added to give the titled product as a solid (0J2g). MS: ESI 427.07 (M+H) H NMR: δ(DMSO) 8.42 (t, IH), 7.94-7.84 (m, 2H), 7.49 (d, IH), 7.29 (m, 3H), 6.98 (dd, IH), 4.44 (m, IH), 3.36 (m, 2H), 2.74 (m, 2H), 2.48 (m, 2H), 2.29 (bt, 2H), 1.92 (m, 2H), 1.60 (m, 2H) Melting point: 118 °C Example 12 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-fluorobenzamide Prepared by the same method as Example 11 using 4-fluorobenzoyl chloride without the addition of 1.0 M ethereal hydrogen chloride solution to give the titled product as a solid (OJg). MS: ESI 411 JO (M+H) J H NMR: δ(DMSO) 10.46 (bs, IH), 9.04 (s, IH), 7.98 (s, IH), 7.90 (d, IH), 7.58 (m, 3H), 7.36 (dd, IH), 7.05 (m, IH), 4.84/4.60 (m, IH), 3.69 (m, 3H), 3.48 (bd, IH), 3.20 (m, 4H), 2.15 (m, 4H) Melting point: 192 °C Example 13 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-3-fluorobenzamide hydrochloride Prepared by the same method as Example 1 1 using 3-fluorobenzoyl chloride to give the titled product as a solid (0.09g). MS: ESI 411 JO (M+H) ! H NMR: δ(DMSO) 10.67 (bs, IH), 9.06 (s, IH), 7.80 (m, 2H), 7.55 (m, 2H), 7.40 (m, 2H), 7.05 (m, IH), 4.84/4.63(m, IH), 3.70 (m, 3H), 3.28 (m, 3H), 2.20 (m, 4H) Melting point: 225 °C Example 14 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyI}-3-hydroxybenzamide hydrochloride The product of Example 10 (0J5g) was dissolved in dichloromethane (10ml) and a solution of l.OM BBr 3 in dichloromethane (4ml) added. After 16 hours at room temperature the solvent was removed by evaporation, methanol was added and the solution concentrated. The residue was dissolved in 2M aqueous HC1 solution, concentrated to dryness and the residue triturated under ether to give the titled product as a solid (OJg). MS: ESI 409.10 (M+H) ! H NMR: δ(DMSO) 9.98-9.4 (bs, 2H), 8.71 (t, IH), 7.6 (dd, IH), 7.4-7.2 (m, 4H), 7.05 (m, IH), 6.95 (dd, IH), 4.65 (m, IH), 3.40 (m, 8H), 2.0 (m, 4H) Melting point: 83-4 °C Example 15 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-3-[2-(methylamino)-2- oxoethoxyjbenzamide hydrochloride (i) [l-(2-AminoethyI)-4-piperidinyl](4-chlorophenyl)methanone trifluoroacetate To a solution of (4-chlorophenyl)(4-piperidinyl)methanone hydrochloride (2.5g) and tert- butyl 2-bromoethylcarbamate (2Jg) in DMF was added triethylamine (2.9g), after 72 hours at room temperature water and ether were added. The organic phase was separated, dried and concentrated. The residue was dissolved in dichloromethane (40 ml), trifluoroacetic acid (10ml) added and the solution left for 20 hours. Evaporation of the solvent gave a sticky solid which was triturated under ether to give the sub-titled product as a solid (2.5g). (ii) N-{2-[4-(4-ChlorobenzoyI)-l-piperidinyl]ethyl}-3-methoxybenzamide hydrochloride The product of step (i) (2.5g) was dissolved in dichloromethane (20ml), triethylamine (0.75ml) and 3-methoxybenzoyl chloride (0.276g) were added. After 16 hours, water was added, the organic phase separated, dried and concentrated to a gum. Purification by chromatography (ethyl acetate) gave a gum, which was treated with 1.OM ethereal hydrogen chloride solution to give the sub-titled product as a solid (0.3g). MS: ESI 401.16 (M+H) H NMR: δ(DMSO) 10.3 (bm, IH), 8.95 (t, IH), 8.0 (m, 2H), 7.6 (m, 2H), 7.5 (m, 2H), 7.4 (t, IH), 7.05 (m, IH), 3.8 (s, 3H), 3.68 (m, 4H), 3.28 (m, 5H), 2.0 (m, 4H). Melting point: 196-7 °C (iii) N-{2-[4-(4-ChIorobenzoyl)-l-piperidinylJethyl}-3-hydroxybenzamide hydrochloride Prepared by the method of Example 14 using the product of step (ii) above (0.24g) to give the sub-titled product as a solid (0.20g). MS: ESI 387.14 (M+H) l H NMR: δ(DMSO) 8.62 (t, IH), 8.05 (dd, 2H), 7.6 (dd, 2H), 7.25 (m, 3H), 6.95 (m, IH), 4.26 (m, 9H), 2.0 (m, 4H) Melting point: 90-91 °C (iv) N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-3-[2-(methylamino)-2- oxoethoxyjbenzamide hydrochloride The product of step (iii) above (0.10g) was dissolved in DMF (3ml), Cs 2 CO 2 (0.23g) and 2-chloro-N-methylacetamide (0.26g) were added and the mixture heated at 80° C for 16 hours. The mixture was cooled to room temperature, water and ethyl acetate were added and the organic phase separated. Evaporation of the solvent gave a gum which was treated with l.OM ethereal hydrogen chloride solution to give the titled product as a solid (0.05g). MS: ESI 458.18 (M+H) H NMR: δ(DMSO) 10.6-10.2 (bm, IH), 8.95 (bm, IH), 8.1 (m, 2H), 7.55 (m, 8H), 7J4 (bd, IH), 4.54 (s, 2H), 4.0 (m, IH), 3.4 (m, 8H), 2.65 (d, 3H), 2.0 (m, 4H) Melting point: 69-70 °C Example 16 2-[3-{2-[4-(4-Fluorobenzoyl)-l-piperidinyIJethyl}-2,4-dioxo-3,4-dihydro-l(2H)- quinazolinyl j -N,N-dimethylacetamide hydrochloride 3- { 2-[4-(4-Fluorobenzoyl)- 1 -piperidinyljethyl } -2,4( 1 H,3H)-quinazolinedione was dissolved in DMF (5ml) and NaH ( 60% dispersion in mineral oil) added. After 0.5 hours, 2-chloro-N,N-dimethylacetamide was added and the solution stirred at room temperature for 16 hours. Water and ethyl actetate were added, the organic phase separated, dried and concentrated to an oil. Purification by chromatography (dichloromethane : methanol 95:5) gave an oil which was treated with 1.0 M ethereal hydrogen chloride solution to give the titled product as a solid(0.015g). MS: ESI 481.22 (M+H) ! H NMR: δ(DMSO) 8.08 (m,3H), 7.76 (t, IH), 7.40 (t, 2H), 7.32 (m, 2H), 5.05 (s, 2H), 4.36 (m, IH), 3.76 (m, 3H), 3.39 (m, 2H), 3.15 (s, 3H), 2.87 (s, 3H), 2.02 (m, 2H), 5 1.81 (m, 2H), 1.28 (m,2H) Melting point: 245-246 °C Example 17 N-{2-[4-(3,4-DichlorobenzoyI)-l-piperazinylJethyl}-3-methoxybenzamide o hydrochloride (i) tert-Butyl 2-(l-piperazinyl)ethylcarbamate A mixture of benzaldehyde (21g) and 1 -(2-aminoethyl)piperazine (25.8g) was stirred and heated under a Dean and Stark water separator for 20 hours. The cooled solution was s treated portionwise with di-tert-butyldicarbonate (48g), stirred for 72 hours and concentrated. The residue was treated with IM aqueous KHSO 4 solution (220ml), stirred for 24hours, ether was added and the organic phase separated. The aqueous phase was treated with 2M NaOH solution, dichloromethane was added and the organic phase separated. The combined organic phase was washed with brine, dried and concentrated to o give the sub-titled product as an oil (30g). MS: APCI(+ve ) 230( M+H) ! H NMR δ (CDC1 3 ) 3.43 (t, 4H), 2.8 (t, 2H ), 2.45 ( m, 6H), 1.5 (s, 9H). 5 (ii) tert-Butyl 2-[4-(3,4-dichlorobenzoyl)-l-piperazinyl]ethylcarbamate The product from step (i) above (3g) was dissolved in pyridine (12ml), 3,4-dichlorobenzoyl chloride (2.05g) was added and the mixture stirred at room temperature for 18 hours. A solid was collected by filtration and purified by chromatography (dichloromethane : methanol : 0.880 NH 4 OH, 90:9: 1) to give the sub-titled product as an oil (3.59g). MS: APCI(+ve ) 364( M+H) l H NMR δ (CDC1 3 ) 7.33 (m, 3H), 7.04 (m, IH), 6.76 (bs, IH), 3.86 (s, 3H), 3.55 (q, 2H), 3.45 (t, 4H), 2.61 (t, 3H), 2.46 (t, 4H), 1.46 (s, 9H) (iii) [4-(2-Aminoethyl)-l-piperazinylJ(3,4-dichlorophenyl)methanone trifluoroacetate The product from step (ii) above (3.3g) was dissolved in dichloromethane (50ml) and trifluoroacetic acid (10ml) added. After 16 hours at room temperature the solvent was removed to give the sub-titled product as an oil (5.9g). MS: APCI(+ve ) 264( M+H) (iv) N-{2-[4-(3,4-Dichlorobenzoyl)-l-piperazinyI]ethyI}-3-methoxybenzamide hydrochloride The product from step (iii) above (0J5g) was dissolved in pyridine (2ml) and 3-methoxybenzoyl chloride (0.064g) added. After 16 hours at room temperature, water and ethyl acetate were added, the organic phase separated, dried and concentrated to an oil. Purification by chromatography (dichloromethane : methanol, 95:5) gave an oil which was treated with 1.0M ethereal hydrogen chloride solution to give the titled product as a solid (0.043g). MS: ESI 436.12 (M+H) l R NMR: δ(DMSO) 8.8 (bt, IH), 7.34 (m, 2H), 7.43 (m, 4H), 7.14(m, IH), 3.82(s, 3H), 3.48 (m,12H) Melting point: 230 °C Example 18 3,4-Dichloro-N-{2-[4-(3,4-dichlorobenzoyl)-l-piperazinyl]ethyl}benzamide A solution of benzaldehyde (5.3g) and l-(2-aminopiperazine) (6.45g) in toluene (100ml) was heated under a Dean and Stark water separator for 4 hours. The solution was cooled to room temperature and triethylamine (5.05g) added. A solution of 3,4-dichlorobenzoyl chloride (10.48g) in toluene (50ml) was added dropwise, the solution stirred at room temperature for 18 hours and water added. The organic phase was separated, dried and concentrated to a residue which was treated with IN aqueous KHSO 4 solution (65ml). The mixture was stirred vigorously for 4 hours, ether was added, the aqueous phase separated and NaOH added. CHC1 3 was added, the organic phase separated, dried and concentrated to a gum. Purification by chromatography (dichloromethane : triethylamine, 95:5) gave the titled product as a foam (0.25g). MS: ESI 474.03 (M+H) ! H NMR: δ(DMSO) 8.8 (bt, IH), 7.34 (m, 2H), 7.43 (m, 4H), 7J4 (m, IH), 3.82 (s, 3H), 3.48 (m, 12H) Example 19 4-Chloro-N-{2-[4-(3,4-dichlorobenzoyl)-l-piperazinylJethyl}-2-[2-(dimethylamino)-2- oxoethoxyjbenzamide hydrochloride The product of Example 26 step (ii) (0.3g), 3,4-dichlorobenzoyl chloride (OJg) and triethylamine (0J5g) were dissolved in dichloromethane (15ml). After 20 hours at room temperature water was added, the organic phase separated, dried and evaporated to give a gum. Purification by chromatography (dichloromethane : methanol, 20: 1) gave a solid which was treated with 1.OM ethereal hydrogen chloride solution to give the titled product as a solid (OJg). MS: ESI 541.11 (M+H) l H NMR δ(DMSO-D6) 9.54 (t, IH), 7.91 (d, IH), 7.74 (m, 2H), 7.43 (m, 2H), 7J8 (d, IH), 5.12 (s, 2H), 3.2-3.8 (m, 12H), 2.99 (s, 3H), 2.88 (s,3H). Melting point: 226-7 °C. Example 20 N~7~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-5-methyl[l,3]thiazolo[4,5- d]pyrimidine-2,7-diamine MS: APCI(+ve) 453 (M+l) Example 21 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-9-methyl-9H-purin-6-amine MS: APCI(+ve) 421 (M+l) Example 22 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-l,3-benzothiazol-2-amine MS: APCI(+ve) 422 (M+l) Example 23 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-l,3-benzoxazol-2-amine MS: APCI(+ve) 406 (M+l) Example 24 6-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyI]ethyI}-2-pyrazinamine MS: APCI(+ve) 403 (M+l) Example 25 6-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-3-pyridazinamine MS: APCI(+ve) 403 (M+l) Example 26 6-({2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}amino)-l,3-dimethyl-2,4(lH,3H)- pyrimidinedione MS: APCI(+ve) 427 (M+l) Example 27 N-{l-[4-(3,4-Dichlorophenoxy)-piperidin-l-ylmethylJ-2-methyl-propyl}-4-methyl- benzamide, hydrochloride (i) N-{l-{4-(3,4-DichIorophenoxy)-piperidine-l-carbonylJ-2-methyl-propyl}-acetamide N-Boc Valine (1.13g) was dissolved in dichloromethane (5 ml) and EDC (0.99g) added, after 5 min the product according to Example 1 step (ii) (1.44g) in dichloromethane (5 ml) was added in one portion. After 3 hours at room temperature, aqueous sodium bicarbonate solution and ethyl acetate were added. The organic phase was separated and the solvent removed to give the sub-titled compound as an oil (1.57 g) which was used in the next step without further purification. (ii) 2-amino-l-[4-(3,4-dichlorophenoxy)-piperidine-l-yI]-3-methyl-butan-l-one The product of step (i) (1.57 g) was dissolved in dichloromethane (14 ml) and trifluoroacetic acid (4 ml) added. After 2 hours at room temperature the solvent was removed, ethyl acetate and 2Ν aqueous NaOH solution were added to give pH 8.0. The organic phase was separated and concentrated to give the sub-titled product as an oil (1.24 g) which was used in the next step without further purification. (iii) l-[4-(3,4-Dichlorophenoxy)-piperidin-l-ylmethyl]-2-methyl-propylamine The product of step (ii) (1.12g) was dissolved in THF (10 ml) and Borane/THF complex (22.7 ml) added. The mixture was heated under reflux for 2 hours and cooled. The solvent was evaporated, the product dissolved in methanol (5ml) and 50% aqueous HCl solution added. The mixture was heated to 70 °C for 1 hour and cooled to room temperature. The solvent was removed, ethyl acetate and 2N aqueous NaOH solution were added to give pH 9.0. The organic phase was separated and the solvent evaporated to give the sub-titled compound as an oil (0.98 g) which used without further purification. (iv) N-{l-[4-(3,4-Dichlorophenoxy)-piperidin-l-ylmethyl]-2-methyl-propyl}-4-methyl- benzamide, hydrochloride The product of step (iii) (0.2g) was dissolved in dichloromethane (5ml), triethylamine (0J26 ml) and 4-methylbenzoyl chloride (0.097 ml) were added. After 2 hours at room temperature, ethyl acetate and aqueous NaHCO 3 solution were added, the organic phase separated and the solvent removed to leave an oil. Purification by reverse phase HPLC (with a gradient eluent system (25% MeCN/NH 4 OAc aq (0.1 %) to 95% MeCN//NH 4 OAc aq (0.1 %)) gave a gum. Addition of 1.0M ethereal hydrogen chloride solution gave the titled product as a solid (0J04 g). Melting point: 131-132°C MS: ESI 450 (M+H) 1H NMR: δ(DMSO) 8.45 (t, IH), 7.00-7.90 (m, 7H), 4.79 (br s, IH), 4.24-4.30 (m, IH), 3.10-3.42 (m, 5H), 2.36 (s, 3H), 1.88-2.40 (m, 5H), 0.92 (t, 6H) Example 28 N-{l-[4-(3,4-Dichloro-phenoxy)-piperidin-l-ylmethylJ-2-methyl-propyl}-3-methoxy- benzamide, hydrochloride The product according to Example 27 step (iii) dissolved in dichloromethane (4 ml), triethylamine (0.090 ml) and 3-methoxybenzoyl chloride (0.077 ml) were added. After 2 hours at room temperature, NaHCO was added, the product extracted with ethyl acetate, the combined organic extracts dried with Na 2 SO and concentrated. Purification with reverse phase HPLC (with a gradient eluent system (25% MeCN/NH 4 OAc aq (0.1%) to 95% MeCN//NH 4 OAc aq (0.1 %)) gave a gum. The product was dissolved in methanol and treated with l.OM ethereal Hydrogen chloride solution to give the product as a solid (0.045 g). MS: ESI 465 (M+H) ] H NMR: δ(DMSO) 8.58-8.63 (m, IH), 7.01-7.58 (m, 6H), 4.80 (br s, IH), 4.23-4.59 (m, IH), 3.83 (s, 3H), 3.04-3.60 (m, 4H), 1.89-2J4 (m, 5H), 0.85 (m, 6H) Example 29 N-{2-[4-(3,4-Dichloroanilino)-l-piperidinyl]ethyl}-3-methoxybenzamide dihydrochloride (i) tert-Butyl 4-(3,4-dichloroanilino)-l-piperidinecarboxylate A solution of 3,4-dichloroaniline (5g), N-tert-butoxycarbonyl-4-piperidone (1 1.7g), sodium triacetoxyborohydride (19.7g) and acetic acid (7ml) in dichloroethane (150ml) was stirred for 16 hours. 2M ΝaOH solution and ether were added, the organic phase separated, dried and concentrated. The residue was triturated under an isohexane : ethyl acetate, 4: 1 mixture and the sub-titled product collected as a solid (7.25g). MS: APCI(+ve) 345 (M+H) H NMR: δ(DMSO) 7.23 (dJH), 6.77 ( dJH), 6.57 ( dd, IH), 5.99 (dJH), 3.85 (bd, 2H), 3.40 (m, IH), 2.90 (bm, 2H), 1.85 (m, 2H), 1.39 (s, 9H), 1J9 (m,2H) (ii) N-(3,4-DichlorophenyI)-4-piperidinamine trifluoroacetate The product of step (i) above (6.5g) was dissolved in dichloromethane (75ml) and trifluoroacetic acid (25ml) added. After 72 hours at room temperature the solution was evaporated and the residue triturated under ether to give the sub-titled product as a solid (6.3g). MS: APCI(+ve) 245/7 (M+H) JJ NMR: δ(DMSO) 8.65 (bs, IH), 8.50 (bs, IH), 7.26 (d, IH), 6.81 (d, IH), 6.60 ( dd, IH), 6J9 (bs, IH), 3.53 (bs, IH), 3.30 (m, 2H), 3.0 (m, 2H), 2.02 (m, 2H), 1.50 (m, 2H) (iii) tert-Butyl 2-[4-(3,4-dichloroanilino)-l-piperidinylJethylcarbamate The product from step (ii) above (2.0g), N-tert-butoxycarbonyl-2-bromoethanamine (l.Og) and N,N-di-isopropylethylamine (3.7ml) were dissolved in DMF (25ml) and stirred for 16 hours. Water and ethyl acetate were added, the organic phase separated, dried and evaporated to give a gum. Purification by chromatography (dichloromethane : methanol, 95:5) gave the sub-titled product as a solid (1.25g). MS: APCI(+ve) 388/90 (M+H) H NMR: δ(DMSO) 7.22 (d, IH), 6.73 (d, IH), 6.62 ( t,lH), 6.54 (dd, IH) 5.94 (d, IH), 3J7 (m, IH), 3.02 (m, 2H), 2.77 (bd, 2H), 2.31 (t, 3H), 2.06 (t, 2H), 1.84 (bd, 2H), 1.35 (m, 11H) (iv) 1 -(2-AminoethyI)-N-(3,4-dichlorophenyl)-4-piperidinamine triluoroacetate The product from step (iii) above (1.2g) was dissolved in dichloromethane (30ml) and trifluoroacetic acid (10ml) added. After 72 hours at room temperature the reaction mixture was evaporated and residue triturated under ether to give the sub-titled product as a solid (1.6g). MS: APCI(+ve) 288/90 (M+H) (v) N-{2-[4-(3,4-Dichloroanilino)-l-piperidinylJethyI}-3-methoxybenzamide dihydrochloride The product of step (iv) above (0.5g) and triethylamine (1.1ml) were dissolved in DMF (10ml), 3-methoxybenzoylchloride (0J 1ml) was added dropwise. After 2 hours, water and ethyl acetate were added, the organic phase separated, dried and evaporated. Purification of the residue by chromatography (dichloromethane : methanol, 95:5) gave an oil which was treated with 1.0M ethereal hydrogen chloride solution to give the titled product as a solid (0J5g). MS: ESI 422.14 (M+H) H NMR: δ(DMSO) 10.44 (bs, IH), 8.93 (t, IH) 7.51 (m, 2H), 7.40 (t, IH), 7.26 (dJH), 7.11 (dd, IH), 6.81 (d, IH), 6.60 (dd, IH), 3.82 (s, 3H), 2.68 (m, 4H), 3.25 (m, 5H), 2.09 (bd, 2H), 1.76 (m, 2H) Melting point: 170 °C Example 30 N-{2-[4-(3,4-DichIorophenoxy)-l-piperidinylJethyl}-N-(3-methoxybenzyl)amine dihydrochloride A suspension of the product of Example 1 step (iv) (0.1 lg) in a mixture of DMF (1.5ml) and 1 ,2-dichloroethane (3ml) was stirred under an atmosphere of nitrogen. Sodium triacetoxyborohydride (0.097 g), 3-methoxybenzaldehyde (0.04 lg) and triethylamine (0.046g) were added and the mixture stirred for 18 hours at room temperature. Chloroform and aqueous NaHCO 3 solution were added, the organic phase separated, dried and concentrated to a gum. Purification by chromatography (chloroform : triethylamine : methanol, 89 J 0:1) gave an oil which was treated with l.OM ethereal hydrogen chloride solution to give the titled product as a solid (0.067g). MS: ESI 409.14 (M+H) ! H NMR: δ(DMSO) 7.50 (d, IH), 7.30 (m, 3H), 7J2 (d, IH), 7.03 (dd, IH), 6.97 (ddJH), 4.71 (bm, IH), 4J8 (s, 2H), 3.80 (s, 3H), 3.45 (bm, 4H), 2.23 (m, 6H), 2.04 (m, 2H), Melting point: 247-51 °C Example 31 3-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}-6-methoxy-2,4(lH,3H)- quinazolinedione (i) 2-Amino-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-5- methoxybenzamide Prepared by the method of Example 2 using the product from Example 1 step (iv) ( 1.0g) and 2-amino-5-methoxybenzoic acid (0.418g) without the addition of l.OM ethereal hydrogen chloride solution to give an oil which was purified by chromatography (dichloromethane : methanol, 95:5) to give the sub-titled product as an oil (0.82g). MS: APCI(+ve) 438 (M+H) (ii) 3-{2-[4-(3,4-DichIorophenoxy)-l-piperidinyl]ethyl}-6-methoxy-2,4(lH,3H)- quinazolinedione The product of step (i) above was dissolved in toluene (10ml). A solution of phosgene 2.0M in toluene (10ml) was added, the solution heated under reflux for 1 hour and cooled. Ethyl acetate and aqueous NaHCU3 solution were added, the organic phase separated, dried and concentrated to leave a residue which was purified by chromatography (dichloromethane : methanol, 95:5). The titled product was obtained as a solid (OJ lg). MS: ESI 464.11 (M+H) l H NMR: δ(DMSO) 7.49 (dd, IH), 7.36 (d, IH), 7.30 (dd, IH), 7.24 (dJH), 6.98 (dd, IH), 444 (m, IH), 4.03 (t, 3H), 3.80 (s, 3H), 2.76 (m, 2H), 2.32 (m, 2H), 1.89 (m, 2H), 1.57 (m, 2H) Melting point: 190 °C The compounds of following Examples 32 to 125 were prepared by methods analogous to the method of Example 10. Example 32 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-fluorobenzamide MS: APC1 (+ve) BP 41 1 Example 33 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}benzamide MS: APC1 (+ve) BP 393 Example 34 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}benzamide MS: APC1 (+ve) BP 429 Example 35 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-methoxybenzamide MS: APC1 (+ve) BP 423 Example 36 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-methoxybenzamide MS: APC1 (+ve)BP423 Example 37 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-methoxybenzamide MS: APC1 (+ve)BP423 Example 38 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-nitrobenzamide MS:APC1 (+ve)BP438 Example 39 N-{2-[4-(3,4-DichIorophenoxy)-l-piperidinyl]ethyl}-2-methylbenzamide MS:APC1 (+ve)BP407 Example 40 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-(trifluoromethyl)benzamide MS: APCl (+ve)BP461 Example 41 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-3,5-dinitrobenzamide MS: APCl(+ve)BP483 Example 42 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-iodobenzamide MS: APC1 (+ve) BP 519 Example 43 4-Cyano-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}benzamide MS: APC1 (+ve) BP 418 Example 44 4-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide MS: APC1 (+ve) BP 473 Example 45 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-methylbenzamide MS: APC1 (+ve) BP 407 Example 46 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-nitrobenzamide MS: APC1 (+ve) BP 438 Example 47 3-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}benzamide MS: APC1 (+ve) BP 473 Example 48 3,4-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide MS: APC1 (+ve) BP 463 Example 49 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-fluorobenzamide MS: APCl (+ve) BP 411 Example 50 2,4-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide MS: APCl (+ve) BP 463 Example 51 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-3-methylbenzamide MS: APCl (+ve) BP 407 Example 52 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-iodobenzamide MS: APCl (+ve) BP 519 Example 53 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-3-nitrobenzamide MS: APCl (+ve) BP 472 Example 54 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-methyl-3-nitrobenzamide MS:APCl(+ve)BP452 Example 55 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-fluoro-5- (trifluoromethyl)benzamide MS:APCl(+ve)BP479 Example 56 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-3-(trifluoromethoxy)benzamide MS: APCl(+ve)BP477 Example 57 3,5-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}benzamide MS: APCl (+ve) BP 463 Example 58 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-(trifluoromethyl)benzamide MS: APCl (+ve) BP 461 Example 59 3-Cyano-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}benzamide MS: APCl (+ve) BP 418 Example 60 2-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-5-methoxybenzamide MS: APCl (+ve)BP503 Example 61 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-furamide MS: APCl (+ve)BP383 Example 62 3-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide MS:APCl(+ve)BP427 Example 63 2-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide MS: APCl (+ve) BP 429 Example 64 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3,5-difluorobenzamide MS: APCl (+ve) BP 429 Example 65 2,3-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}benzamide MS: APCl (+ve) BP 463 Example 66 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-naphthamide MS: APCl (+ve) BP 442 Example 67 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(methylsulfanyl)nicotinamide MS: APCl (+ve) BP 440 Example 68 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-fluoro-6- (trifluoromethyl)benzamide MS: APCl (+ve)BP479 Example 69 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}-2,4-difluorobenzamide MS: APCl (+ve)BP429 Example 70 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-thiophenecarboxamide MS:APCl(+ve)BP399 Example 71 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyI}-2-quinoxaIinecarboxamide MS: APCl (+ve)BP445 Example 72 Methyl 4-({2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}amino)-4-oxobutanoate MS: APCl (+ve) BP 403 Example 73 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}bicyclo[2.2J]hept-5-ene-2- carboxamide MS: APCl (+ve) BP 409 Example 74 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}cycIobutanecarboxamide MS:APCl(+ve)BP371 Example 75 N -{ 2- [4- (3,4-Dichlorophenoxy ) - 1 -piperidinyljethyl } -2-methoxyacetamide MS: APCl (+ve)BP361 Example 76 N-{2-[4-(3,4-DichIorophenoxy)-l-piperidinylJethyl}cyclohexanecarboxamide MS: APCl (+ve) BP 399 Example 77 (E)-N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-phenyl-2-propenamide MS: APCl (+ve) BP 419 Example 78 2-Chloro-N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}nicotinamide MS: APCl (+ve) BP 430 Example 79 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-phenylacetamide MS: APCl (+ve)BP407 Example 80 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}cyclopentanecarboxamide MS: APCl (+ve)BP385 Example 81 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}-2-phenoxyacetamide MS: APCl (+ve)BP423 Example 82 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyI]ethyl}benzamide MS: APCl (+ve) BP 371 Example 83 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-3-(trifluoromethyI)benzamide MS: APCl (+ve) BP 439 Example 84 4-(tert-Butyl)-N-{2-[4-(4-chlorobenzoyl)-l-piperidinylJethyl}benzamide MS: APCl (+ve) BP 427 Example 85 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyl}-4-methylbenzamide MS: APCl (+ve) BP 385 Example 86 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyl}-4-nitrobenzamide MS: APCl (+ve) BP 416 Example 87 N-{2-[4-(4-ChlorobenzoyI)-l-piperidinyl]ethyl}-3-methylbenzamide MS: APCl (+ve) BP 385 Example 88 N-{2-[4-(4-ChlorobenzoyI)-l-piperidinyIJethyl}-4-methyl-3-nitrobenzamide MS: APCl (+ve) BP 430 Example 89 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyI}-3-cyanobenzamide MS: APCl (+ve) BP 396 Example 90 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-2-furamide MS: APCl (+ve) BP 361 Example 91 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyl}-3-nitrobenzamide MS: APCl (+ve) BP 416 Example 92 N-{2-[4-(4-ChIorobenzoyl)-l-piperidinylJethyl}-2-naphthamide MS: APCl (+ve)BP421 Example 93 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyI}-2-(methylsulfanyl)nicotinamide MS: APCl(+ve)BP418 Example 94 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-2-(2,3-dihydro-l,4-benzodioxin-2-yl)- 1 ,3-thiazole-4-carboxamide MS: APCl (+ve) BP 512 Example 95 N~2~-Cyclopropyl-N~4— {2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-2,4- pyrimidinediamine MS: APCI(+ve) 422 (M+l) Example 96 2-{[4-({2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}amino)-2-pyrimidinyl]amino}- 1 -ethanol MS: APCI(+ve) 426 (M+l) Example 97 2-[[4-({2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}amino)-2- pyrimidinyl](methyl)amino]-l-ethanol MS: APCI(+ve) 440 (M+l) Example 98 N~4—{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-N~2~-phenyl-2,4- pyrimidinediamine MS: APCI(+ve) 458 (M+l) Example 99 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyIJethyI}-2-(methylsulfanyl)-4- pyrimidinamine MS: APCI(+ve) 413 (M+l) Example 100 N~4—{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyI}-6-methyl-2,4- pyrimidinediamine MS: APCI(+ve) 396 (M+l) Example 101 N~4~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyIJethyl}-N~2~,6-dimethyl-2,4- pyrimidinediamine MS: APCI(+ve) 410 (M+l) Example 102 2-Chloro-N~4~-cyclopropyI-N~6~-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}- 4,6-pyrimidinediamine MS: APCI(+ve) 456 (M+l) Example 103 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-phenyI-2-pyrimidinamine MS: APCI(+ve) 443 (M+l) Example 104 N~2~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-N~4~,N~4~,6-trimethyl-2,4- pyrimidinediamine MS: APCI(+ve) 424 (M+l) Example 105 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-(trifluoromethyl)-2- pyrimidinamine MS: APCI(+ve) 435 (M+l) Example 106 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}-4-(propylsulfanyl)-2- pyrimidinamine MS: APCI(+ve) 441 (M+l) Example 107 N~2~-{2-[4-(3,4-DichIorophenoxy)-l-piperidinylJethyl}-N~4~-phenyl-2,4- pyrimidinediamine MS: APCI(+ve) 458 (M+l) Example 108 N~4—Cyclopropyl-N~2~-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2,4- pyrimidinediamine MS: APCI(+ve) 422 (M+l) Example 109 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}[l,8Jnaphthyridin-2-amine MS: APCI(+ve) 417 (M+l) Example 110 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-(3-pyridinyl)-2-pyrimidinamine MS: APCI(+ve) 444 (M+l) Example 111 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-pyrimidinamine MS: APCI(+ve) 367 (M+l) Example 112 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4,6-dimethoxy-2-pyrimidinamine MS: APCI(+ve) 427 (M+l) Example 113 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-(3-furyl)-2-pyrimidinamine MS: APCI(+ve) 433 (M+l) Example 114 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}-l-methyl-lH-pyrazolo[3,4- dJpyrimidin-4-amine MS: APCI(+ve) 421 (M+l) Example 115 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-lH-purin-6-amine MS: APCI(+ve) 407 (M+l) Example 116 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-5-methylthieno[2,3-dJpyrimidin- 4-amine MS: APCI(+ve) 437 (M+l) Example 117 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-7-methylthieno[3,2-dJpyrimidin- 4-amine MS: APCI(+ve) 437 (M+l) Example 118 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-2-thiophenecarboxamide MS: APCl (+ve) BP 377 Example 119 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-2-quinoxalinecarboxamide MS: APCl (+ve) BP 423 Example 120 N-{2-[4-(4-ChlorobenzoyI)-l-piperidinyl]ethyl}bicycIo[2.2J]hept-5-ene-2- carboxamide MS: APCl (+ve) BP 387 Example 121 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}cyclohexanecarboxamide MS: APCl (+ve) BP 377 Example 122 (E)-N-{2-[4-(4-ChlorobenzoyI)-l-piperidinylJethyl}-3-phenyl-2-propenamide MS: APCl (+ve) BP 397 Example 123 N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-2-phenoxyacetamide MS: APCl (+ve) BP 401 Example 124 (E)-N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-3-(4-nitrophenyl)-2-propenamide MS: APCl (+ve) BP 442 Example 125 2-(l-Adamantyl)-N-{2-[4-(4-chIorobenzoyl)-l-piperidinyl]ethyl}acetamide MS: APCl (+ve) BP 443 The compounds of following Examples 126 to 168 were prepared by methods analogous to the method of Example 30. Example 126 (4-Chlorophenyl)(l-{2-[(2-fluoro-4,5-dimethoxybenzyl)amino]ethyl}-4- piperidinyl)methanone MS: APCl (+ve) BP 435 Example 127 (4-Chlorophenyl)(l-{2-[(3,4,5-trimethoxybenzyl)aminoJethyl}-4- piperidinyl)methanone MS: APCl (+ve) BP 447 Example 128 (4-ChlorophenyI)(l-{2-[(3-nitrobenzyl)amino]ethyl}-4-piperidinyl)methanone MS: APCl (+ve) BP 402 Example 129 (4-ChlorophenyI){l-[2-(isobutylamino)ethylJ-4-piperidinyl}methanone MS:APCl(+ve)BP323 Example 130 4-[({2-[4-(4-ChlorobenzoyI)-l-piperidinylJethyl}amino)methylJ-4-ethylhexanenitrile MS: APCl (+ve)BP404 Example 131 (4-Chlorophenyl)(l-{2-[(7-hydroxy-3,7-dimethyloctyl)aminoJethyI}-4- piperidinyl)methanone MS: APCl (+ve)BP423 Example 132 (4-Chlorophenyl)[l-(2-{[(6-nitro-l,3-benzodioxoI-5-yI)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 446 Example 133 [l-(2-{[(5-Chloro-l,3-dimethyl-lH-pyrazol-4-yl)methyl]amino}ethyl)-4-piperidinylJ(4- chlorophenyl)methanone MS: APCl (+ve) BP 409 Example 134 (4-Chlorophenyl)[l-(2-{[3-nitro-4-(2-pyridinylsulfanyl)benzyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 511 Example 135 (4-Chlorophenyl)[l-(2-{[(E)-3-(4-nitrophenyl)-2-propenyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 428 Example 136 (4-Chlorophenyl){l-[2-({[5-(3-nitrophenyl)-2-furyl]methyl}amino)ethyl]-4- piperidinyljmethanone MS: APCl (+ve) BP 468 Example 137 (4-Chlorophenyl)[l-(2-{[5-nitro-2-(2-pyridinylsulfanyI)benzyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 511 Example 138 6-[({2-[4-(4-ChlorobenzoyI)-l-piperidinylJethyI}amino)methyI]-2- (methylsulfanyl)nicotinonitrile MS: APCl (+ve) BP 429 Example 139 {l-[2-({[5-Chloro-l-methyI-3-(trifluoromethyl)-lH-pyrazol-4-ylJmethyl}amino)ethylJ- 4-piperidinyl}(4-chlorophenyl)methanone MS: APCl (+ve) BP 463 Example 140 (4-ChIorophenyl)[l-(2-{[3-(methylsuIfanyI)butyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 369 Example 141 (4-Chlorophenyl)[l-(2-{[(4-phenyl-4-piperidinyI)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 440 Example 142 (4-ChlorophenyI)[l-(2-{[(l-phenyl-lH-pyrazoI-5-yl)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 423 Example 143 Ethyl 3-[({2-[4-(4-chlorobenzoyI)-l-piperidinyl]ethyl}- amino)methyl]cyclohexanecarboxylate MS: APCl (+ve) BP 435 Example 144 N-{4-[({2-[4-(4-Chlorobenzoyl)-l-piperidinyI]ethyl}amino)methylJphenyl}acetamide MS: APCl (+ve) BP 414 Example 145 (4-ChlorophenyI)(l-{2-[(2,5-difluorobenzyI)aminoJethyl}-4-piperidinyl)methanone MS: APCl (+ve) BP 393 Example 146 (4-Chlorophenyl)(l-{2-[(4-nitrobenzyl)amino]ethyl}-4-piperidinyl)methanone MS: APCl (+ve) BP 402 Example 147 (4-Chlorophenyl)(l-{2-[(2,6-dichlorobenzyl)amino]ethyl}-4-piperidinyl)methanone MS: APCl (+ve)BP425 Example 148 (4-Chlorophenyl)(l-{2-[(2-pyridinylmethyl)aminoJethyl}-4-piperidinyl)methanone MS:APCl(+ve)BP358 Example 149 (4-Chlorophenyl)[l-(2-{[(3-methyl-2-thienyl)methylJamino}ethyl)-4- piperidinyljmethanone MS:APCl(+ve)BP377 Example 150 (4-Chlorophenyl)(l-{2-[(3-hydroxy-4-methoxybenzyI)aminoJethyl}-4- piperidinyl)methanone MS: APCl (+ve) BP 403 Example 151 3-[({2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}amino)methyl]-4H-chromen-4-one MS: APCl (+ve) BP 425 Example 152 [l-(2-{[(5-Chloro-l,3-dimethyl-lH-pyrazol-4-yl)methylJamino}ethyl)-4-piperidinyl](4- chlorophenyl)methanone MS: APCl (+ve) BP 409 Example 153 (4-Chlorophenyl)[l-(2-{[(2,6-dichloro-4-pyridinyl)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 428 Example 154 (4-Chlorophenyl)[l-(2-{[(2-phenyl-lH-imidazol-4-yl)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve)BP423 Example 155 (4-Chlorophenyl)[l-(2-{[(5-ethyl-2-thienyl)methylJamino}ethyl)-4- piperidinyljmethanone MS:APCl(+ve)BP391 Example 156 (4-Chlorophenyl)[l-(2-{[(2-chloro-3-quinolinyl)methylJamino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 442 Example 157 (4-Chlorophenyl)[l-(2-{[(6-methyI-2-pyridinyl)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 372 Example 158 (4-Chlorophenyl)(l-{2-[(3-quinolinylmethyl)amino]ethyl}-4-piperidinyl)methanone MS: APCl (+ve) BP 408 Example 159 4-[({2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}amino)methylJ-l,5-dimethyl-2- phenyl-l,2-dihydro-3H-pyrazol-3-one MS: APCl (+ve) BP 467 Example 160 (4-Chlorophenyl)(l-{2-[(4-pyridinylmethyl)amino]ethyl}-4-piperidinyl)methanone MS: APCl (+ve) BP 358 Example 161 (4-Chlorophenyl)(l-{2-[(3-hydroxy-4-nitrobenzyl)amino]ethyl}-4- piperidinyI)methanone MS: APCl (+ve) BP 418 Example 162 (4-Chlorophenyl)(l-{2-[(3,5-difluorobenzyl)aminoJethyl}-4-piperidinyl)methanone MS: APCl (+ve) BP 393 Example 163 (l-{2-[(2-Chloro-6-fluorobenzyl)amino]ethyl}-4-piperidinyl)(4- chlorophenyl)methanone MS: APCl (+ve) BP 409 Example 164 [l-(2-{[(4-Bromo-lH-pyrazol-3-yl)methyl]amino}ethyl)-4-piperidinyl](4- chlorophenyl)methanone MS: APCl (+ve) BP 427 Example 165 3-[({2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}amino)methyl]-6,7-dimethyl-4H- chromen-4-one MS: APCl (+ve) BP 453 Example 166 2-{2-[({2-[4-(4-ChlorobenzoyI)-l-piperidinylJethyl}amino)methyl]-4- nitrophenoxy}acetic acid MS: APCl (+ve) BP 476 Example 167 (4-ChIorophenyl)[l-(2-{[(l-methyl-lH-benzimidazol-2-yl)methyl]amino}ethyl)-4- piperidinyljmethanone MS: APCl (+ve) BP 411 Example 168 (4-ChlorophenyI)[l-(2-{[(2,4-dimethoxy-5-pyrimidinyl)methyl]amino}ethyI)-4- piperidinyljmethanone MS:APCl(+ve)BP419 The compounds of following Examples 169 to 209 were prepared by methods analogous to the method of Example 2. Example 169 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4-(methylamino)benzamide MS: APCl (+ve)BP422 Example 170 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-3-methoxybenzamide MS: APCl (+ve)BP459 Example 171 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}-3-methoxy-4-methyIbenzamide MS: APCl (+ve)BP437 Example 172 MS:APCl(+ve)BP438 Example 173 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyIJethyl}-l,3-benzodioxole-5-carboxamide MS: APCl (+ve)BP437 Example 174 4-Amino-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-3-methoxybenzamide MS: APCl (+ve) BP 438 Example 175 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-fluoro-4-methoxybenzamide MS: APCl (+ve) BP 441 Example 176 5-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2-furamide MS: APCl (+ve) BP 463 Example 177 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-methyl-2-furamide MS: APCl (+ve) BP 397 Example 178 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4,5-dimethyl-2-furamide MS: APCl (+ve) BP 411 Example 179 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-7-ethoxy-l-benzofuran-2- carboxamide MS: APCl (+ve) BP 477 Example 180 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-5-methoxy-l-benzofuran-2- carboxamide MS: APCl (+ve) BP 463 Example 181 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-7-methoxy-l-benzofuran-2- carboxamide MS: APCl (+ve) BP463 Example 182 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-(4-fluorophenyI)acetamide MS: APCl (+ve) BP 425 Example 183 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(2-methoxyphenyl)acetamide MS: APCl (+ve) BP 437 Example 184 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(3-methylphenyl)acetamide Cl MS: APCl (+ve) BP421 Example 185 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(2-methylphenyl)acetamide C Cl MS: APCl (+ve) BP 421 Example 186 2-(3-Bromophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyI}acetamide MS: APCl (+ve) BP 487 Example 187 2-(2-Chlorophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyI}acetamide MS: APCl (+ve) BP 441 Example 188 2-(4-Chlorophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyI}acetamide MS: APCl (+ve) BP 443 Example 189 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-[2- (trifluoromethyl)phenyl]acetamide MS: APCl (+ve) BP 475 Example 190 2-(3-Chlorophenyl)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}acetamide C MS: APCl (+ve) BP441 Example 191 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-(3,4- dimethoxyphenyl)acetamide MS: APCl (+ve) BP467 Example 192 N-{2-[4-(3,4-DichIorophenoxy)-l-piperidinyl]ethyl}-2-(4-methoxyphenyl)acetamide C MS: APCl (+ve) BP 437 Example 193 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-(3,4-dichlorophenyl)acetamide MS: APCl (+ve) BP 477 Example 194 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}-2-(3-fluoro-4- methoxyphenyl)acetamide MS: APCl (+ve) BP 455 Example 195 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(4-ethoxyphenyl)acetamide MS: APCl (+ve) BP 451 Example 196 2-(l,3-Benzodioxol-5-yl)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}acetamide MS: APCl (+ve) BP451 Example 197 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-[4- (dimethylamino)phenyl]acetamide MS: APCl (+ve) BP 450 Example 198 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-(4-methylphenyl)acetamide MS: APCl (+ve)BP421 Example 199 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-2-(3,4-difluorophenyl)acetamide Cl MS: APCl (+ve)BP443 Example 200 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}-2-(3-methoxyphenyl)acetamide MS: APCl (+ve)BP437 Example 201 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}-4-phenylbutanamide MS: APCl (+ve) BP 435 Example 202 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-phenylpropanamide MS: APCl (+ve) BP 421 Example 203 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-(3- methoxyphenyl)propanamide MS: APCl (+ve) BP 451 Example 204 2-Amino-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-l,3-thiazole-4- carboxamide MS: APCl (+ve) BP 416 Example 205 2-(Acetylamino)-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-l,3-thiazole-4- carboxamide MS: APCl (+ve) BP 457 Example 206 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(4-pyridinyl)-l,3-thiazoIe-4- carboxamide MS: APCl (+ve) BP 477 Example 207 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2,4-dimethyl-l,3-thiazole-5- carboxamide MS: APCl (+ve) BP 428 Example 208 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2,5-dimethyl-l,3-oxazole-4- carboxamide MS: APCl (+ve) BP 412 Example 209 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyI}-lH-imidazole-4-carboxamide MS: APCl (+ve) BP 385. Example 210 N-{2-[4-(3,4-Chlorophenoxy)-l-piperidinyl]ethyl}-3-methoxybenzamide hydrochloride (i) 2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethylamine trifluoroacetate Prepared by the method of Example 1 steps (i) to (iv) using 3-chlorophenol to give the product as an oil (0.5 g) which was used directly in the next step without further purification. (ii) N-{2-[4-(3,4-Chlorophenoxy)-l-piperidinylJethyl}-3-methoxybenzamide hydrochloride The product of step (i) above (0.3g) was dissolved in dichloromethane (490ml), triethylamine (4 equiv) and 3-methoxybenzoyl chloride (1 equiv) were added. After 72 hours at room temperature, water was added, the organic phase separated, dried and concentrated to a gum. The product was dissolved in dichloromethane and treated with 1.0M ethereal hydrogen chloride solution to give the titled product as a solid (0J g). Melting point: 175-176 °C MS: APCI(+ve): 389(M+H) Η NMR: δ(DMSO) 8.87 (t, IH), 7.5 (m, 2H), 7.42 (m, IH), 7.32 (m, IH), 7J3 (m, 2H), 6.98 (m, 2H), 4.82 (m, 1/2H), 4.61 (m,l/2H), 3.81 (s, 3H), 3.69 (m, 3H), 3.68 (m, 3H), 347 (m, IH), 3J3-3.22 (m, 4H), 2.27 (m, IH), 2J4 (m, IH), 2.03 (m, IH), 1.90 (m, IH) Example 211 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyI}-l-methyl-lH-pyrazolo[3,4- dJpyrimidin-4-amine (i) 2-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-lH-isoindole-l,3(2H)-dione A solution of the product from Example 1 step (ii) (2.0g), 2-(3-bromopropyl)-lH- isoindole-l,3(2H)-dione (1.61g) and triethylamine (2.5ml) in dichloromethane (40ml) was heated under reflux for 48h. The reaction mixture was partitioned between ethyl acetate/water, the organic layer dried and evaporated under reduced pressure. Purification was by chromatography eluting with 4% methanol/dichloromethane. Yield 0.839g MS: APCI(+ve) 433 (M+l) (ii) 3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propylamine, dihydrochloride salt The product from step (i) (0.83g) and hydrazine hydrate (OJml) in ethanol was heated under reflux for 6h. The precipitate was filtered off and partitioned between 2M hydrochloric acid and dichloromethane, the solid was filtered off and the aqueous layer basified with aqueous potassium hydroxide solution and extracted with dichloromethane. The organic layer was dried, evaporated under reduced pressure and the dihydrochloride salt formed using ethereal hydrogen chloride. Yield 0.28g 2 H NMR: δ(DMSO-d 6 ) l l.H(br s, IH), 8J3(br s, 3H), 7.56 (d, lH), 7.37(s, IH), 7.10- 7.06(br m, IH), 4.84(br s, 0.5H), 4.65(br s,0.5H), 3.60-2.90(m, 8H), 2.24-2.01 (m, 6H). (iii) N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-l-methyl-lH-pyrazolo[3,4- d]pyrimidin-4-amine The product from step (ii) (0.08g), 4-chloro-l-mefhyl-lH-pyrazolo[3,4-dJpyrimidine (0.054g) and diisopropylethylamine (0.082g) in l-methyl-2-pyrrolidinone (2ml) was heated at 50°C for 3h. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried and the solvent removed under reduced pressure. Purification was by chromatography eluting with 9% methanol/dichloromethane. Yield 0.052g MS: APCI(+ve) 435 (M+l) H NMR: δ(DMSO-d 6 ) 8.25-8.22(m, 2H), 8.07(s, IH), 7.49(d, IH), 7.25(d, IH), 6.97(dd, IH), 4.46-4.42(m, IH), 3.88(s, 3H), 3.49(q, 2H), 2.70-2.66(m, 2H), 2.40-2.36(m, 2H), 2.27-2.22(m, 2H), 1.92-1.88(m, 2H), 1.81-1.74(m, 2H), 1.62-1.59(m, 2H). Melting point: 120- 124°C Examples 212-255 The product from Example 211 step (ii) (1.5mg), the appropriate activated halo aromatic (1.25 equivalents), diisopropylethylamine (10 equivalents) in l-methyl-2-pyrrolidinone (0J5ml) were heated at 100°C for 24h. The reaction mixture was evaporated to dryness and the residue dissolved in dimethylsulphoxide (0.4ml). Example 212 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyI}-2,6-dimethoxy-4- pyrimidinamine MS: APCI(+ve) 441 (M+l) Example 213 N~4~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyI}-N~2~,N~2~-dimethyl-2,4- pyrimidinediamine MS: APCI(+ve) 424 (M+l) Example 214 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-2-[(methylsuIfanyl)methyl]-4- pyrimidinamine MS: APCI(+ve) 441 (M+l) Example 215 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyI}-2-(methylsulfanyl)-6- (trifluoromethyI)-4-pyrimidinamine MS: APCI(+ve) 495 (M+l) Example 216 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-5-methoxy-2-(methylsuIfanyl)-4- pyrimidinamine MS : APCI(+ve) 457 (M+ 1 ) Example 217 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-6-methyl-2-(methylsulfanyl)-4- pyrimidinamine MS: APCI(+ve) 441 (M+l) Example 218 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyI}-5-methoxy-2-methyl-4- pyrimidinamine MS : APCI(+ve) 425 (M+ 1 ) Example 219 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-2-(ethylsulfanyl)-6-methyl-4- pyrimidinamine MS: APCI(+ve) 455 (M+l) Example 220 N~2~-Cyclopropyl-N~4~-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-2,4- pyrimidinediamine MS: APCI(+ve) 436 (M+l) Example 221 2-{[4-({3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}amino)-2- pyrimidinylJamino}-l-ethanol MS: APCI(+ve) 440 (M+l) Example 222 2-[[4-({3-[4-(3,4-Dichlorophenoxy)-l-piperidinyIJpropyl}amino)-2- l o pyrimidinyl] (methyl)amino] -1 -ethanol MS: APCI(+ve) 454 (M+l) Example 223 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-2-(methylsulfanyl)-4- pyrimidinamine MS : APCI(+ve) 427 (M+ 1 ) Example 224 N~4~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyI}-6-methyl-2,4- pyrimidinediamine MS: APCI(+ve) 410 (M+l) Example 225 N~4~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-N~2~,6-dimethyl-2,4- pyrimidinediamine MS : APCI(+ve) 424 (M+ 1 ) Example 226 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyI}-4-phenyI-2-pyrimidinamine MS: APCI(+ve) 457 (M+l) Example 227 N~2~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-5-fluoro-2,4- pyrimidinediamine MS: APCI(+ve) 414 (M+l) Example 228 N~2—{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyI}-N~4~,N~4~,6-trimethyl-2,4- pyrimidinediamine MS: APCI(+ve) 438 (M+l) Example 229 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-4-(trifluoromethyl)-2- pyrimidinamine MS : APCI(+ve) 449 (M+ 1 ) Example 230 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-4-(propylsulfanyl)-2- pyrimidinamine MS: APCI(+ve) 455 (M+l) Example 231 N~2~- {3-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]propyl}-N~4~- phenyl-2,4- pyrimidinediamine MS : APCI(+ve) 472 (M+ 1 ) Example 232 N~2— {3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-N~4~,6-dimethyI-2,4- pyrimidinediamine MS: APCI(+ve) 424 (M+l) Example 233 N-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}[l,8Jnaphthyridin-2-amine MS: APCI(+ve) 431 (M+l) Example 234 2-{[2-({3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyI}amino)-4- pyrimidinyl]amino}-l -ethanol MS : APCI(+ve) 440 (M+ 1 ) Example 235 2-[[2-({3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}amino)-4- pyrimidinyl] (methy l)amino] - 1 -ethanol MS : APCI(+ve) 454 (M+ 1 ) Example 236 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-4-(3-pyridinyl)-2- pyrimidinamine MS: APCI(+ve) 458 (M+l) Example 237 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]propyl}-4-(3-thienyl)-2-pyrimidinamine MS: APCI(+ve) 463 (M+l) Example 238 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-2-pyrimidinamine MS: APCI(+ve) 381 (M+l) Example 239 N-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}-4,6-dimethoxy-2- pyrimidinamine MS: APCI(+ve) 441 (M+l) Example 240 N-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}-4-(3-furyI)-2-pyrimidinamine MS: APCI(+ve) 447 (M+l) Example 241 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-4-(2-thienyl)-2-pyrimidinamine MS: APCI(+ve) 463 (M+l) Example 242 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-lH-purin-6-amine MS: APCI(+ve) 421 (M+l) Example 243 N-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}-5-methylthieno[2,3- d]pyrimidin-4-amine MS: APCI(+ve) 451 (M+l) Example 244 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-7-methylthieno[3,2- d]pyrimidin-4-amine MS: APCI(+ve) 451 (M+l) Example 245 N~7~-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}-5-methyI[l,3]thiazolo[4,5- dJpyrimidine-2,7-diamine MS: APCI(+ve) 467 (M+l) Example 246 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-9-methyI-9H-purin-6-amine MS: APCI(+ve) 435 (M+l) Example 247 N-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}-2-pyridinamine MS: APCI(+ve) 379 (M+l) Example 248 5-Chloro-N-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-2-pyridinamine MS: APCI(+ve) 414 (M+l) Example 249 6-Chloro-N-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-2-pyridinamine MS: APCI(+ve) 414 (M+l) Example 250 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-6-methyl-2-pyridinamine MS: APCI(+ve) 494 (M+l) Example 251 N-{3-[4-(3,4-DichIorophenoxy)-l-piperidinyl]propyl}-l,3-benzothiazol-2-amine MS: APCI(+ve) 436 (M+l) Example 252 N-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-l,3-benzoxazol-2-amine MS: APCI(+ve) 420 (M+l) Example 253 6-Chloro-N-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-2-pyrazinamine MS: APCI(+ve) 415 (M+l) Example 254 6-Chloro-N-{3-[4-(3,4-dichlorophenoxy)-l-piperidinyl]propyl}-3-pyridazinamine MS: APCI(+ve) 417 (M+l) Example 255 6-({3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}amino)-l,3-dimethyl- 2,4(lH,3H)-pyrimidinedione MS: APCI(+ve) 441 (M+l) Examples 256-292 The product from Example 1 step (iv) (2.07mg), the appropriate activated halo aromatic (1.25 equivalents), diisopropylethylamine (10 equivalents) in l-methyl-2-pyrrolidinone (0J5ml) were heated at 100°C for 24h.. The reaction mixture was evaporated to dryness and the residue dissolved in dimethylsulphoxide (0.4ml). Example 256 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyI}-2,6-dimethoxy-4-pyrimidinamine MS: APCI(+ve) 427 (M+l) Example 257 N~4~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-N~2~,N~2~-dimethyl-2,4- pyrimidinediamine MS: APCI(+ve) 410 (M+l) Example 258 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyI}-2-[(methylsuIfanyl)methyl]-4- pyrimidinamine MS: APCI(+ve) 427 (M+l) Example 259 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-5-methoxy-2-(methylsulfanyl)-4- pyrimidinamine MS: APCI(+ve) 443 (M+l) Example 260 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyI]ethyl}-6-methyl-2-(methylsulfanyl)-4- pyrimidinamine MS: APCI(+ve) 427 (M+l) Example 261 N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-5-methoxy-2-methyl-4- pyrimidinamine MS: APCI(+ve) 411 (M+l) Example 262 N~4~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-6-methyl-N~2—phenyI-2,4- pyrimidinediamine MS: APCI(+ve) 472 (M+l) Pharmacological Analysis Calcium flux [Ca 2+ ]j assay a) Human eosinophils Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., J. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended (5xl0 6 ml "1 ) and loaded with 5μM FLUO-3/AM + Pluronic F127 2.2μl/ml (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO 4 0.8mM, glucose 5.5mM, Na 2 CO 3 8.5mM, KCl 5mM, HEPES 20mM, CaCl 2 1.8mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at 2.5x10 6 ml "1 . The cells were then transferred to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with 5μM fibronectin for two hours) at lOOml/well. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS (200μl; room temperature). A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1 %(v/v) DMSO. Assays were initiated by the addition of an A 50 concentration of eotaxin and the transient increase in fluo-3 fluorescence (1 EX =490nm and I EΠ . = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.). b) Human monocytes Human monocytes were isolated from EDTA anticoagulated peripheral blood as previously described (Cunoosamy & Holbrook, J. Leukocyte Biology, 1998, S2, 13). Cells were resuspended (5xl0 6 ml "1 ) in LKS and loaded with 5μM FLUO-3/AM + Pluronic F127 2.2μl/ml (Molecular Probes) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at 0.5x10 6 ml "1 . The cells were then transferred to 96 well FLIPr plates (Costar). To each well lOOμl of cells were added at a concentration of 0.5x10 6 ml "1 . The plates were centrifuged (200g; 5 mins; room temperature) to allow the cells to adhere. After centrifugation the cells were washed twice with LKS (200μl; room temperature). A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1 %(v/v) DMSO. Assays were initiated by the addition of an A 50 concentration of MlP-lα and the transient increase in fluo-3 fluorescence (1 EX =490nm and l Em = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.). The compounds of the Examples were found to be antagonists of the eotaxin mediated [Ca 2+ ]i in human eosinophils and/or antagonists of the MlP-lα mediated [Ca 2+ J; in human monocytes. Human eosinophil chemotaxis Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., /. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended at lOxlO 6 ml "1 in RPMI containing 200 IU/ml penicillin, 200 μg/ml streptomycin sulphate and supplemented with 10% HIFCS, at room temperature. Eosinophils (700 μl) were pre-incubated for 15 mins at 37° C with 7 μl of either vehicle or compound (lOOx required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, 3μm pore, Neuroprobe) was loaded by adding 28μl of a concentration of eotaxin (0J to lOOnM) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and 25 μl of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO 2 atmosphere to allow chemotaxis. The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 μl of PBS containing 0.5% Triton xlOO followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., J. Immunol. Methods, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant. Certain compounds of the Examples were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis.

Claims: C L A I M S 1. A compound of general formula R 1 - (Q) m -T- (CR 2 R 3 )— V W-X— R ' (I) wherein: R represents a C]-Ci2 alkyl group optionally substituted by one or more substituents independently selected from cyano, hydroxyl, Cj-Cg alkoxy, Cj-Cg alkylthio and Cj-Cg alkoxycarbonyl groups, or R represents a 3- to 10-membered saturated or unsaturated ring system which may comprise up to two ring carbon atoms that form carbonyl groups and which may comprise up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur, the ring system being optionally substituted by one or more substituents independently selected from halogen atoms, and cyano, nitro, hydroxyl, Cj-Cg alkyl, C3-C6 cycloalkyl, C]-C6 alkoxy, C\ -C(, alkoxycarbonyl, -C6 haloalkyl, C\ -C^ haloalkoxy, -NR R , C3-C6 cycloalkylamino, Cj-Cg alkylthio, C1-C6 aikylthioCi-C alkyl, 7 8 -C6 alkylcarbonylamino, -C(O)NR R , sulphonamido, (di)Cι-C6 alkylsulphonamido, phenyl, phenylamino, nitrophenyl, pyridyl, pyridylthio, benzodioxanyl, thienyl, 9 furanyl, and C(O)R -substituted Ci-C alkyl or Cj-Cg alkoxy groups; m is 0 or 1 ; Q represents a group OCH2, C1-C4 alkylene or C2-C4 alkenylene; T represents a group C(O)NH, or when m is 0, T may additionally represent a bond or a group NH, or when m is 1 and Q represents -C4 alkylene, T may additionally represent a group NH; n is 1, 2, 3 or 4; 2 each R independently represents a hydrogen atom or a -C4 alkyl group; 3 each R independently represents a hydrogen atom or a C1-C4 alkyl group; V represents a nitrogen atom; W represents a nitrogen atom or a group CH; X represents an oxygen atom or a group C(O), CH(OH), NH or N(Cι-Cg alkyl), provided that when W represents a nitrogen atom, then X represents C(O); 4 R represents a phenyl group optionally substituted by one or more substituents independently selected from halogen atoms, and amino, nitro, cyano, sulphonyl, sulphonamido, Ci-Cg alkyl, C \ -C^ haloalkyl, Cj-Cg haloalkoxy and Ci-C6 alkylsulphonyl groups; R and R each independently represent a hydrogen atom or a Cj-Cg alkyl or hydroxyCj-Cό alkyl group, or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; 7 8 R and R each independently represent a hydrogen atom or a Cj-Cό alkyl group; and 9 7 8 R represents a hydroxyl or -NR R group; with the provisos that 2 3 (a) when m is 0, T is CONH, n is 2, 3 or 4 and each R and R represents hydrogen, W is CH, X is C(O) or CH(OH) and R represents a substituted 3- to 10-membered unsaturated ring system, then the one or more substituents in the ring system do not include hydroxyl, halogen, Cj-Cό alkoxy or Cj-Cό haloalkoxy, and 4 (b) when W is N, X is C(O), R represents 3-trifluoromethylphenyl, m is 0 and T is a 1 2 3 bond, then R and (CR R ) n taken together do not represent a C1-C6 alkyl group, and 2 3 (c) when W is CH, X is O, n is 2 or 3 and each R and R represents hydrogen, m is 0 and T is NH, then R does not represent a group or a pharmaceutically acceptable salt or solvate thereof. 2. A compound according to claim 1, wherein R represents a Cj-Cio alkyl group optionally substituted by one or two substituents independently selected from cyano, hydroxyl, -C4 alkoxy, -C4 alkylthio and C1-C4 alkoxycarbonyl groups, or R represents a 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur, the ring system being optionally substituted by one, two or three substituents independently selected from halogen atoms, and cyano, nitro, hydroxyl, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C1-C4 alkoxycarbonyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, -NR R , C3- cycloalkylamino, -C4 alkylthio, -C4 alkylthioCι-C4 alkyl, 7 8 C1-C4 alkylcarbonylamino, -C(O)NR R , phenyl, phenylamino, nitrophenyl, pyridyl, 9 pyridylthio, benzodioxanyl, thienyl, furanyl, and C(O)R -substituted C1-C4 alkyl or C1-C4 alkoxy groups. 3. A compound according to claim 1 or claim 2, wherein m is 1 and Q represents a group OCH2, C1-C3 alkylene or C2-C3 alkenylene. 4. A compound according to any one of claims 1 to 3, wherein T represents a group C(O)NH. 5. A compound according to any one of the preceding claims, wherein n is 2 or 3. 6. A compound according to any one of the preceding claims, wherein V represents a nitrogen atom and W represents a group CH. 7. A compound according to any one of the preceding claims, wherein X represents an oxygen atom or a group C(O) or NH. 4 8. A compound according to any one of the preceding claims, wherein R represents a phenyl group optionally substituted by one or two halogen atoms. 9. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to claim 1 being selected from: 4-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2-[2-(dimethylamino)-2- oxoethoxy]benzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-3-ethoxybenzamide hydrochloride, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-4-isopropoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-4-ethoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-3-(trifluoromethoxy)benzamide hydrochloride, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-4-methoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(trifluorome thoxy)benzamide hydrochloride, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-furamide hydrochloride, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-phenylacetamide hydrochloride, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide hydrochloride, 3-Chloro-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide hydrochloride, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-fluorobenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-ρiperidinyl]ethyl}-3-fluorobenzamide hydrochloride, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-hydroxybenzamide hydrochloride, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-[2-(methylamino)-2- oxoethoxyjbenzamide hydrochloride, 2-[3-{2-[4-(4-Fluorobenzoyl)-l-piperidinylJethyl}-2J-dioxo-3J-dihydro-l(2H)- quinazolinylJ-N,N-dimethylacetamide hydrochloride, N- { 2-[4-(3,4-Dichlorobenzoyl)- 1 -piperazinyljethyl } -3-methoxybenzamide hydrochloride, 3,4-Dichloro-N-{2-[4-(3,4-dichlorobenzoyl)-l-piperazinyl]ethyl}benzamide, 4-Chloro-N-{2-[4-(3,4-dichlorobenzoyl)-l-piperazinyl]ethyl}-2-[2-(dimethylamino)-2- oxoethoxyjbenzamide hydrochloride, N~7~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-5-methyl[l,3]thiazolo[4,5- d]pyrimidine-2,7-diamine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-9-methyl-9H-purin-6-amine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-benzothiazol-2-amine, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-benzoxazol-2-amine, 6-Chloro-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } -2-pyrazinamine, 6-Chloro-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyl]ethyl } -3-pyridazinamine, 6-( { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } amino)- 1 ,3-<ϋmethyl-2,4( 1 H,3H)- pyrimidinedione, N- { 1 - [4-(3 ,4-Dichlorophenoxy)-piperidin- 1 -ylmethyl] -2-methyl-propyl } -4-methyl- benzamide, hydrochloride salt, N- { 1 -[4-(3,4-Dichloro-phenoxy)-piperidin- 1 -ylmethylJ-2-methyl-propyl } -3-methoxybenzamide, hydrochloride salt, N-{2-[4-(3,4-Dichloroanilino)-l -piperidinyljethyl} -3-methoxybenzamide dihydrochloride, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -N-(3-methoxybenzyl)amine dihydrochloride, 3- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -6-methoxy-2,4( 1 H,3H)- quinazolinedione, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-fluorobenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl Jbenzamide, 4-Chloro-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl Jbenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-methoxybenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-methoxybenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-nitrobenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2-methylbenzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-(trifluoromethyl)benzamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3,5-dinitrobenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-iodobenzamide, 4-Cyano-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide, 4-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl Jbenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-methylbenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-nitrobenzamide, 3-Bromo-N-{2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl Jbenzamide, 3J-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl Jbenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-fluorobenzamide, 2,4-Dichloro-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl Jbenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-methylbenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-iodobenzamide, 4-Chloro-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -3-nitrobenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-methyl-3-nitrobenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-fluoro-5- (trifluoromethyl)benzamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-(trifluoromethoxy)benzamide, 3,5-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl Jbenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(trifluoromethyl)benzamide, 3-Cyano-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } benzamide, 2-Bromo-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } -5-methoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyl] ethyl } -2-furamide, 3-Chloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl Jbenzamide, 2-Chloro-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyl]ethyl } benzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-3,5-difluorobenzamide, 2, 3-Dichloro-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl Jbenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-naphthamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(methylsulf anyl)nicotinamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-fluoro-6- (trifluoromethyl)benzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,4-difluorobenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-thiophenecarboxamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-quinoxalinecarboxamide, Methyl 4-( { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } amino)-4-oxobutanoate, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }bicyclo[2.2.1Jhept-5-ene-2- carboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl Jcyclobutanecarboxamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-methoxyacetamide, N- 2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}cyclohexanecarboxamide, (E; N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-3-phenyl-2-propenamide, 2-Chloro-N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } nicotinamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl J -2-phenylacetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl Jcyclopentanecarboxamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-phenoxyacetamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl Jbenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-(trifluoromethyl)benzamide, 4-(tert-Butyl)-N-{2-[4-(4-chlorobenzoyl)-l -piperidinyljethyl Jbenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -4-methylbenzamide, N-{2-[4-(4-Chlorobenzoyl)-l-piperidinylJethyl}-4-nitrobenzamide, N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-3-methylbenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -4-methyl-3-nitrobenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-cyanobenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-furamide, N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}-3-nitrobenzamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-naphthamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyl]ethyl } -2-(methylsulfanyl)nicotinamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-(2,3-dihydro- 1 ,4-benzodioxin-2-yl)- 1 ,3- thiazole-4-carboxamide, N~2~-Cyclopropyl-N~4~- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -2,4- pyrimidinediamine, 2- { [4-( { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } amino)-2-pyrimidinyl J amino } - 1 - ethanol, 2-[[4-( { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } amino)-2- pyrimidinyl] (methyl)aminoj - 1 -ethanol , N~4~- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -N~2~-phenyl-2,4- pyrimidinediamine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(methylsulfanyl)-4-pyrimidinamine, N~4~- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -6-mefhyl-2,4-pyrimidinediamine, N~4~- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -N~2~,6-dimethyl-2,4- pyrimidinediamine, 2-Chloro-N~4~-cyclopropyl-N~6~- (2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl} -4,6- pyrimidinediamine, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-phenyl-2-pyrimidinamine, N~2~-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-N~4~,N~4~,6-trimethyl-2J- pyrimidinediamine, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(trifluoromethyl)-2- pyrimidinamine, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinylJethyl}-4-(propylsulfanyl)-2-pyrimidinamine, N~2~- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -N~4~-phenyl-2,4- pyrimidinediamine, N~4—Cyclopropyl-N~2—{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-2J- pyrimidinediamine, N-{2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }[l,8]naphthyridin-2-amine, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(3-pyridinyl)-2-pyrimidinamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-pyrimidinamine, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinylJethyl}-4,6-dimethoxy-2-pyrimidinamine, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-4-(3-furyl)-2-pyrimidinamine, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 -methyl- 1 H-pyrazolo [3 ,4- d]pyrimidin-4-amine, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 H-purin-6-amine, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -5-methylthieno[2,3-d]pyrimidin-4- amine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -7-methylthieno [3 ,2-d]pyrimidin-4- amine, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-thiophenecarboxamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -2-quinoxalinecarboxamide, N-{2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}bicyclo[2.2JJhept-5-ene-2-carboxamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyl]ethyl jcyclohexanecarboxamide, (E)-N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-phenyl-2-propenamide, N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyl]ethyl } -2-phenoxyacetamide, (E)-N- { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } -3-(4-nitrophenyl)-2-propenamide, 2-( 1 -Adamantyl)-N- { 2-[4-(4-chlorobenzoyl)- 1 -piperidinyljethyl } acetamide, (4-Chlorophenyl)( 1 - { 2- [(2-fluoro-4,5-dimethoxybenzyl)amino]ethyl } -4- piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(3J,5-trimethoxybenzyl)amino]ethyl}-4-piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(3-nitrobenzyl)aminoJethyl}-4-piperidinyl)methanone, (4-Chlorophenyl){ l-[2-(isobutylamino)ethylJ-4-piperidinyl}methanone, 4-[({2-[4-(4-Chlorobenzoyl)-l -piperidinyljethyl Jamino)methylJ-4-ethylhexanenitrile, (4-Chlorophenyl)(l-{2-[(7-hydroxy-3,7-dimethyloctyl)aminoJethyl}-4- piperidinyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [(6-nitro- 1 ,3-benzodioxol-5-yl)methylJamino }ethyl)-4- piperidinyljmethanone, [l-(2-{ [(5-Chloro-l ,3-dimethyl-lH-pyrazol-4-yl)methylJamino}ethyl)-4-piperidinylJ(4- chlorophenyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [3-nitro-4-(2-pyridinylsulfanyl)benzyl]amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(E)-3-(4-nitrophenyl)-2-propenylJ amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) { 1 -[2-( { [5-(3-nitrophenyl)-2-furyl]methyl } amino)ethylJ-4- piperidinyl } methanone, (4-Chlorophenyl)[l-(2-{[5-nitro-2-(2-pyridinylsulfanyl)benzylJamino}ethyl)-4- piperidinyljmethanone, 6-[({ 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methylJ-2- (methylsulfanyl)nicotinonitrile, { 1 -[2-( { [5-Chloro- 1 -methyl-3-(trifluoromethyl)- 1 H-pyrazol-4-yl]methyl } amino)ethyl]-4- piperidinyl } (4-chlorophenyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [3-(methylsulfanyl)butylJamino }ethyl)-4-piperidinylJmethanone, (4-Chlorophenyl) [ 1 -(2- { [(4-phenyl-4-piperidinyl)methyl J amino } ethyl)-4- piperidinyl ] methanone , (4-Chlorophenyl) [ 1 -(2- { [( 1 -phenyl- 1 H-pyrazol-5-yl)methylJ amino } ethyl)-4- piperidinyljmethanone, Ethyl 3-[({2-[4-(4-chlorobenzoyl)-l-piperidinyl]ethyl}- amino)methyljcyclohexanecarboxylate, N- { 4-[( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methyl]phenyl } acetamide, (4-Chlorophenyl)( 1 - { 2-[(2,5-difluorobenzyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl)( 1 - { 2-[(4-nitrobenzyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(2,6-dichlorobenzyl)aminoJethyl}-4-piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(2-pyridinylmethyl)amino]ethyl}-4-piperidinyl)methanone, (4-Chlorophenyl) [ 1 -(2- { [(3-methyl-2-thienyl)methyl J amino } ethyl)-4- piperidinyl] methanone, (4-Chlorophenyl)( 1 - { 2-[(3-hydroxy-4-methoxybenzyl)aminoJethyl } -4- piperidinyl)methanone, 3-[({2-[4-(4-Chlorobenzoyl)-l -piperidinyljethyl }amino)methyl]-4H-chromen-4-one, [ 1 -(2- { [(5-Chloro- 1 ,3-dimethyl- 1 H-pyrazol-4-yl)methylJ amino } ethyl)-4-piperidinylJ(4- chlorophenyl)methanone, (4-Chlorophenyl)[l-(2-{ [(2,6-dichloro-4-pyridinyl)methyl]amino}ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(2-phenyl- 1 H-imidazol-4-yl)methyl] amino } ethyl)-4- piperidinyl]methanone, (4-Chlorophenyl) [ 1 -(2- { [(5-ethyl-2-thienyl)methyl]amino } ethyl)-4-piperidinyl Jmethanone, (4-Chlorophenyl)[l-(2-{ [(2-chloro-3-quinolinyl)methylJamino}ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(6-methyl-2-pyridinyl)methylJ amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl)(l-{2-[(3-quinolinylmethyl)amino]ethyl}-4-piperidinyl)methanone, 4-[( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methylJ- 1 ,5-dimethyl-2-phenyl- l,2-dihydro-3H-pyrazol-3-one, (4-Chlorophenyl)( 1 - { 2-[(4-pyridinylmethyl)aminoJethyl } -4-piperidinyl)methanone, (4-Chlorophenyl)( 1 - { 2-[(3-hydroxy-4-nitrobenzyl)amino]ethyl } -4-piperidinyl)methanone, (4-Chlorophenyl)(l-{2-[(3,5-difluorobenzyl)amino]ethyl}-4-piperidinyl)methanone, (l-{2-[(2-Chloro-6-fluorobenzyl)amino]ethyl}-4-piperidinyl)(4-chlorophenyl)methanone, [l-(2-{ [(4-Bromo-lH-pyrazol-3-yl)methylJamino}ethyl)-4-piperidinylJ(4- chlorophenyl)methanone, 3-[({2-[4-(4-Chlorobenzoyl)-l-piperidinyl]ethyl}amino)methyl]-6,7-dimethyl-4H- chromen-4-one, 2- { 2- [( { 2-[4-(4-Chlorobenzoyl)- 1 -piperidinyljethyl } amino)methyl]-4-nitrophenoxy } acetic acid, (4-Chlorophenyl) [ 1 -(2- { [( 1 -methyl- 1 H-benzimidazol-2-yl)methyl]amino } ethyl)-4- piperidinyljmethanone, (4-Chlorophenyl) [ 1 -(2- { [(2,4-dimethoxy-5-pyrimidinyl)methyl]amino } ethyl)-4- piperidinyljmethanone, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-(methylamino)benzamide, 4-Chloro-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxy-4-methylbenzamide, 3-Amino-N-{2-[4-(3J-dichlorophenoxy)-l-piperidinyl]ethyl}-4-methoxybenzamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-benzodioxole-5-carboxamide, 4- Amino-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-fluoro-4-mefhoxybenzamide, 5-Bromo-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinyl]ethyl}-2-furamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-3-methyl-2-furamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-4,5-dimethyl-2-furamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-7-ethoxy- 1 -benzofuran-2- carboxamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -5-methoxy- 1 -benzofuran-2- carboxamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-7-methoxy- 1 -benzofuran-2- carboxamide, N-{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(4-fluorophenyl)acetamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(2-methoxyphenyl)acetamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3-methylphenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-2-(2-methylphenyl)acetamide, 5 2-(3-Bromophenyl)-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } acetamide, 2-(2-Chlorophenyl)-N- { 2-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljethyl } acetamide, 2-(4-Chlorophenyl)-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2- [2- (trifluoromethyl)phenyl]acetamide, l o 2-(3-Chlorophenyl)-N- { 2- [4-(3 ,4-dichlorophenoxy)- 1 -piperidinylj ethyl } acetamide, N-{2-[4-(3J-Dichlorophenoxy)-l-piperidinyl]ethyl}-2-(3,4-dimethoxyphenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(4-methoxyphenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3,4-dichlorophenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3-fluoro-4- 15 methoxyphenyl)acetamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(4-ethoxyphenyl)acetamide, 2-( 1 ,3-Benzodioxol-5-yl)-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2- [4- (dimethylamino)phenyl]acetamide, 20 N- { 2- [4-(3, 4-Dichl orophenoxy)- 1 -piperidinyljethyl } -2-(4-methylphenyl)acetamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3 ,4-difluorophenyl)acetamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(3-methoxyphenyl)acetamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -4-phenylbutanamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-phenylpropanamide, 25 N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -3-(3-methoxyphenyl)propanamide, 2-Amino-N-{2-[4-(3,4-dichlorophenoxy)-l-piperidinylJethyl}-l,3-thiazole-4-carboxamide, 2-( Acetylamino)-N- { 2-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljethyl } - 1 ,3-thiazole-4- carboxamide, N- { 2-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2-(4-pyridinyl)- 1 ,3-thiazole-4- 30 carboxamide, N- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,4-dimethyl- 1 ,3-thiazole-5- carboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,5-dimethyl- 1 ,3-oxazole-4- carboxamide, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } - 1 H-imidazole-4-carboxamide, N- { 2-[4-(3,4-Chlorophenoxy)- 1 -piperidinyljethyl } -3-methoxybenzamide, hydrochloride salt, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 -methyl- 1 H-pyrazolo[3,4- d]pyrimidin-4-amine, N-{3-[4-(3J-Dichlorophenoxy)-l-piperidinyl]propyl}-2,6-dimethoxy-4-pyrimidinamine, N~4~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]propyl}-N~2~,N~2~-dimethyl-2J- pyrimidinediamine, N- { 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2- [(methylsulf anyl)methyl J -4- pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2-(methylsulfanyl)-6- (trifluoromethyl)-4-pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-methoxy-2-(methylsulfanyl)-4- pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-6-methyl-2-(methylsulfanyl)-4- pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-methoxy-2-methyl-4- pyrimidinamine, N- { 3- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-2-(ethylsulfanyl)-6-methyl -4- pyrimidinamine, N~2~-Cyclopropyl-N~4—{ 3-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropyl } -2,4- pyrimidinediamine, 2- { [4-( { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-2-pyrimidinyl] amino } - 1 - ethanol, 2-[[4-( { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-2- pyrimidinyl] (methyl)aminoj - 1 -ethanol , N-{3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-2-(methylsulf anyl)-4- pyrimidinamine, N~4~- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -6-methyl-2,4- pyrimidinediamine, N~4— { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -N~2~,6-dimethyl-2,4- pyrimidinediamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -4-phenyl-2-pyrimidinamine, N~2~-{3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-5-fluoro-2J-pyrimidinediamine, N~2—{3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-N~4~,N~4~,6-trimethyl-2,4- pyrimidinediamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-4-(trifluoromethyl)-2- pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -4-(propylsulf anyl)-2- pyrimidinamine, N~2~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-N~4—phenyl-2,4- pyrimidinediamine, N-2~-{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-N~4~,6-dimethyl-2J- pyrimidinediamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } [ 1 ,8Jnaphthyridin-2-amine, 2- { [2-( { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-4-pyrimidinyl] amino } - 1 - ethanol, 2-[[2-( { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } amino)-4- pyrimidinyl](methyl)amino]- 1 -ethanol, N-{3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-4-(3-pyridinyl)-2-pyrimidinamine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -4-(3-thienyl)-2-pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyrimidinamine, N-{3-[4-(3J-Dichlorophenoxy)-l-piperidinyl]propyl}-4,6-dimethoxy-2-pyrimidinamine, N-{3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-4-(3-furyl)-2-pyrimidinamine, N-{3-[4-(3,4-Dichlorophenoxy)-l -piperidinyljpropyl }-4-(2-thienyl)-2-pyrimidinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 H-purin-6-amine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -5-methylthieno[2,3-d]pyrimidin-4- amine, N- {3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-7-methylthieno[3,2-d]pyrimidin-4- amine, 5 N~7—{3-[4-(3,4-Dichlorophenoxy)-l-piperidinylJpropyl}-5-methyl[l,3]thiazolo[4,5- dJpyrimidine-2,7-diamine, N-{3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-9-methyl-9H-purin-6-amine, N- { 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyridinamine, 5-Chloro-N- { 3-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyridinamine, l o 6-Chloro-N- { 3-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyridinamine, N-{ 3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl }-6-methyl-2-pyridinamine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 ,3-benzothiazol-2-amine, N- { 3-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljpropyl } - 1 ,3-benzoxazol-2-amine, 6-Chloro-N- { 3-[4-(3,4-dichlorophenoxy)- 1 -piperidinyljpropyl } -2-pyrazinamine, 15 6-Chloro-N- {3-[4-(3 ,4-dichlorophenoxy)- 1 -piperidinyljpropyl }-3-pyridazinamine, 6-({3-[4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljpropyl} amino)- l,3-dimethyl-2,4( 1H,3H)- pyrimidinedione, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2,6-dimethoxy-4-pyrimidinamine, N~4~- { 2-[4-(3,4-Dichlorophenoxy)- 1 -piperidinyljethyl }-N~2~,N~2~-dimethyl-2J- 20 pyrimidinediamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -2- [(methylsulfanyl)methyl J -4- pyrimidinamine, N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -5-methoxy-2-(methylsulfanyl)-4- pyrimidinamine, 25 N- { 2- [4-(3 ,4-Dichlorophenoxy)- 1 -piperidinyljethyl } -6-methyl-2-(methylsulfanyl)-4- pyrimidinamine, N-{2-[4-(3,4-Dichlorophenoxy)-l -piperidinyljethyl }-5-mefhoxy-2-methyl-4- pyrimidinamine, and N~4—{2-[4-(3,4-Dichlorophenoxy)-l-piperidinyl]ethyl}-6-methyl-N~2~-phenyl-2J- 30 pyrimidinediamine. 10. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises (i) when T represents a group C(O)NH, reacting a compound of general formula R 1 -(Q) m -COL 1 (π) wherein L represents a leaving group (e.g. a hydroxyl or halide, such as chloride, group) and R , m and Q are as defined in formula (I), with a compound of general formula 2 3 4 oorr aann aacciidd aaddddiittiioonn ssaalltt tthheerreeooff ((<e.g. tπfluoroacetate) wherein n, R , R , V, W, X and R are as defined in formula (I); or (ii) when T represents a group C(O)NH and W represents a nitrogen atom, reacting a compound of general formula R 1 - (Q) m -T- 1 2 3 wherein R , m, Q, T, n, R , R and V are as defined in formula (I), with a compound of general formula L 2 - X - R 4 (V) 2 4 wherein L represents a leaving group (e.g. a halogen atom) and X and R are as defined in formula (I); or (iii) when T represents a group NH and m is 0, reacting a compound of general formula R 1 - L 3 (VI) 3 1 wherein L represents a leaving group (e.g. a halogen atom) and R is as defined in formula (I), with a compound of formula (HI) as defined in (i) above; or (iv) when T represents a group NH, m is 1 and Q represents -C4 alkylene, reacting a compound of general formula R , -(CH 2 ) p -CHO (Vπ) wherein p is 0, 1, 2 or 3 and R is as defined in formula (I), with a compound of formula (HI) as defined in (i) above; or (v) when T represents a bond and m is 0, reacting a compound of general formula R 1 -(CR 2 R 3 ) n -L 4 (Vffl) 4 1 2 wherein L represents a leaving group such as a halogen atom (e.g. chlorine) and n, R , R 3 and R are as defined in formula (I), with a compound of general formula (IX) 4 wherein W, X and R are as defined in formula (I); and optionally after (i), (ii), (iii), (iv) or (v) converting the compound of formula (I) to a further compound of formula (I) and/or forming a pharmaceutically acceptable salt or solvate of the compound of formula (I). 11. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 9 in association with a pharmaceutically acceptable adjuvant, diluent or carrier. 12. A process for the preparation of a pharmaceutical composition as claimed in claim 1 1 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 9 with a pharmaceutically acceptable adjuvant, diluent or carrier. 13. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 9 for use in therapy. 14. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in therapy. 15. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 9 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial. 16. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 9.

Inventors: BAXTER ANDREW, BROUGH STEPHEN, KINDON NICHOLAS, MCINALLY THOMAS, ROBERTS BRYAN, THOM STEPHEN, BAXTER, ANDREW, BROUGH, STEPHEN, KINDON, NICHOLAS, MCINALLY, THOMAS, ROBERTS, BRYAN, THOM, STEPHEN
Applicants: ASTRAZENECA AB, ASTRAZENECA UK LTD, BAXTER ANDREW, BROUGH STEPHEN, KINDON NICHOLAS, MCINALLY THOMAS, ROBERTS BRYAN, THOM STEPHEN, ASTRAZENECA UK LIMITED, BAXTER, ANDREW, BROUGH, STEPHEN, KINDON, NICHOLAS, MCINALLY, THOMAS, ROBERTS, BRYAN, THOM, STEPHEN
Application year: 2000
Main classification: C07D401
IPC codes: A61K31, A61P1, A61P3, A61P9, A61P11, A61P17, A61P19, A61P29, A61P31, A61P37, A61P43, C07D211, C07D217, C07D241, C07D295, C07D401, C07D405, C07D409, C07D413, C07D417, C07D471, C07D473, C07D487, C07D495, C07D513